Cancer – an overview

  • PMID: 29952494

Cancer is characterized by proliferation of cells that have managed to evade central endogenous control mechanisms. Cancers are grouped according to their organ or tissue of origin, but increasingly also based on molecular characteristics of the respective cancer cells. Due to the rapid technological advances of the last years, it is now possible to analyze the molecular makeup of different cancer types in detail within short time periods. The accumulating knowledge about development and progression of cancer can be used to develop more precise diagnostics and more effective and/or less toxic cancer therapies. In the long run, the goal is to offer to every cancer patient a therapeutic regimen that is tailored to his individual disease and situation in an optimal way.

Publication types

  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Precision Medicine
  • Antineoplastic Agents
  • U.S. Department of Health & Human Services

National Institutes of Health (NIH) - Turning Discovery into Health

  • Virtual Tour
  • Staff Directory
  • En Español

You are here

Nih research matters.

April 10, 2018

Genomic analysis of 33 cancer types completed

At a glance.

  • Using molecular and clinical information from more than 10,000 tumors, researchers finished a detailed genomic analysis of 33 types of cancer.
  • This better understanding of how, where, and why cancer develops will inform the development of novel and more personalized treatment approaches.

Squamous cell carcinoma, a type of skin cancer

Cancer is caused by changes to DNA that affect the way cells grow and divide. There are at least 200 forms of cancer, with many subtypes. Identifying the changes in each cancer’s complete set of DNA—its genome—and understanding how these changes interact to drive the disease will lay the foundation for improving cancer prevention, early detection, and tailored treatments.

The Cancer Genome Atlas (TCGA) was launched in 2005 by NIH’s National Human Genome Research Institute (NHGRI) and National Cancer Institute (NCI) to map the key genomic changes in 33 types of cancer . The multi-institution collaboration focused not only on cancer genome sequencing, but also on different types of molecular data collection and analysis, such as investigating gene and protein expression profiles (when they are turned on or off) and associating them with clinical and imaging data. With over $300 million in total funding, the project involved more than 150 researchers at more than two dozen institutions.

The PanCancer Atlas sums up the work accomplished by TCGA in a collection of 27 papers across a suite of Cell journals. Three summary papers published on April 5, 2018, recap the core findings, and companion papers report more in-depth explorations.

The first summary paper describes a technique called molecular clustering that groups cancers based on their molecular characteristics rather than their tissue of origin. The scientists analyzed gene expression, DNA modifications, protein expression, and other data from about 10,000 tissue samples representing 33 different types of cancer. The team identified 28 distinct clusters based on molecular similarities. Although most of these clusters could be linked to tissue of origin, many contained different cancer types. The most diverse group had 25 cancer types. These findings could help guide the treatment of many cancer patients whose tumors are of unknown origin.

The second paper presents findings on oncogenesis, the processes that lead to cancer development and progression. The authors focused on three critical oncogenic processes: the DNA mutations that drive cancers; the influence of DNA alterations on gene and protein expression; and the interplay of tumors with their surroundings, particularly immune cells. The results will help in the development of new treatments for a wide range of cancers.

The final paper details genomic alterations in 10 key signaling pathways that control the stages of the cell’s life cycle, growth, and death. The researchers found that 89% of tumors had at least one significant alteration in these pathways. About 57% of tumors had at least one alteration that could be targeted with currently known drugs and 30% had multiple targetable alterations. These findings will help researchers explore treatments with more tailored approaches, such as using a combination of drugs to target multiple pathways at the same time.

“TCGA was the first project of its scale to characterize—at the molecular level—cancer across a breadth of cancer types,” says Dr. Carolyn Hutter, NHGRI team lead for TCGA. “At the project’s infancy 10 years ago, it wasn’t even possible, much less on such a scale, to do the types of characterization and analysis that were being proposed. It was a hugely ambitious project.”

“The PanCancer Atlas effort complements the over 30 tumor-specific papers that have been published by TCGA in the last decade and expands upon earlier pan-cancer work that was published in 2013,” says Dr. Jean Claude Zenklusen, director of the TCGA Program Office at NCI.

Related Links

  • The Genomics of Cervical Cancer
  • Genomic Diversity of Metastases Among Men With Prostate Cancer
  • Novel Approach Gives Insights Into Tumor Development
  • Study Uncovers Alterations in Head and Neck Cancers
  • Gene Changes Identified in Most Common Lung Cancer
  • Genome Study Yields Insights Into Bladder Cancer
  • Genomic Analysis of Endometrial Tumors
  • New Insights Into Breast Cancer
  • Colon and Rectal Cancers Surprisingly Similar
  • A Detailed Look at Ovarian Cancer
  • A Genomic Survey of Melanoma
  • Mutations Affect Acute Myeloid Leukemia Treatment Outcomes
  • Study Reveals Large Number of Cancer Genes
  • The Genetic Underpinnings of Cancer
  • The Cancer Genome Atlas

References:  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell . 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022. PMID: 29625048. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; Cancer Genome Atlas Research Network. Cell . 2018 Apr 5;173(2):305-320.e10. doi: 10.1016/j.cell.2018.03.033. PMID: 29625049. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Cell . 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035. PMID: 29625050. The entire collection of papers comprising the PanCancer Atlas are available through a portal on cell.com .

Funding:  NIH’s National Human Genome Research Institute (NHGRI) and National Cancer Institute (NCI).

Connect with Us

  • More Social Media from NIH

U.S. flag

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

  • Publications
  • Account settings
  • Advanced Search
  • Journal List
  • Ann Afr Med
  • v.18(3); Jul-Sep 2019

Logo of annafrmed

Language: English | French

Inflammation and Cancer

Nitin singh.

Department of Pedodontics and Preventive Dentistry, Chandra Dental College and Hospital, Safedabad, Barabanki, Uttar Pradesh, India

Deepak Baby

1 Department of Conservative and Endodontics, P.S.M Dental College and Research Centre, Akkikavu, Thrissur, Kerala, India

Jagadish Prasad Rajguru

2 Department of Oral Pathology and Microbiology, Hi-Tech Dental College and Hospital, Bhubaneswar, Odisha, India

Pankaj B Patil

3 Department of Oral and Maxillofacial Surgery, School of Dental Sciences, Krishna Institute of Health Sciences Deemed to be University, Karad, Maharashtra, India

Savita S Thakkannavar

4 Department of Oral Pathology and Microbiology, Tatyasaheb Kore Dental College and Research Centre, New Pargaon, Kolhapur, Maharashtra, India

Veena Bhojaraj Pujari

5 Department of Oral Medicine and Radiology, Tatyasaheb Kore Dental College and Research Centre, New Pargaon, Kolhapur, Maharashtra, India

Inflammation is often associated with the development and progression of cancer. The cells responsible for cancer-associated inflammation are genetically stable and thus are not subjected to rapid emergence of drug resistance; therefore, the targeting of inflammation represents an attractive strategy both for cancer prevention and for cancer therapy. Tumor-extrinsic inflammation is caused by many factors, including bacterial and viral infections, autoimmune diseases, obesity, tobacco smoking, asbestos exposure, and excessive alcohol consumption, all of which increase cancer risk and stimulate malignant progression. In contrast, cancer-intrinsic or cancer-elicited inflammation can be triggered by cancer-initiating mutations and can contribute to malignant progression through the recruitment and activation of inflammatory cells. Both extrinsic and intrinsic inflammations can result in immunosuppression, thereby providing a preferred background for tumor development. The current review provides a link between inflammation and cancer development.

Résumé

L’inflammation est souvent associée au développement et à la progression du cancer. Les cellules responsables de l’inflammation associée au cancer sont génétiquement stables et ne subissent donc pas l’émergence rapide d’une pharmacorésistance; par conséquent, le ciblage de l’inflammation représente une stratégie attrayante à la fois pour la prévention du cancer et pour le traitement du cancer. L’inflammation tumorale extrinsèque est causée par de nombreux facteurs, notamment: infections bactériennes et virales, maladies auto-immunes, obésité, tabagisme, exposition à l’amiante et consommation excessive d’alcool, le tout qui augmentent le risque de cancer et stimulent la progression maligne. En revanche, l’inflammation intrinsèque au cancer ou provoquée par le cancer peut être déclenchée par des mutations initiant un cancer et peuvent contribuer à la progression maligne par le recrutement et l’activation de cellules inflammatoires. Tous les deux les inflammations extrinsèques et intrinsèques peuvent entraîner une immunosuppression, fournissant ainsi un fond préféré pour le développement de la tumeur. le l’examen actuel établit un lien entre l’inflammation et le développement du cancer.

I NTRODUCTION

The presence of leukocytes within tumors, observed in the 19 th century by Rudolf Virchow, provided the first indication of a possible link between inflammation and cancer. Yet, it is only during the past decade that clear evidence has been obtained that inflammation plays a critical role in tumorigenesis.[ 1 ]

However, when inflammation becomes chronic or lasts too long, it can prove harmful and may lead to disease. The role of pro-inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes has been linked with chronic inflammation [ Figure 1 ].[ 2 ]

An external file that holds a picture, illustration, etc.
Object name is AAM-18-121-g001.jpg

Different faces of inflammation and its role in tumorigenesis

Chronic inflammation has been found to mediate a wide variety of diseases, including cardiovascular diseases, cancer, diabetes, arthritis, Alzheimer's disease, pulmonary diseases, and autoimmune diseases.[ 3 ]

The current review, however, will be restricted to the role of chronic inflammation in cancer. Chronic inflammation has been linked to various steps involved in tumorgenesis, including cellular transformation, promotion, survival, proliferation, invasion, angiogenesis, and metastasis.[ 4 ]

Only a minority of all cancers are caused by germline mutations, whereas the vast majority (90%) are linked to somatic mutations and environmental factors. Many environmental causes of cancer and risk factors are associated with some form of chronic inflammation. Up to 20% of cancers are linked to chronic infections, 30% can be attributed to tobacco smoking and inhaled pollutants (such as silica and asbestos), and 35% can be attributed to dietary factors (20% of cancer burden is linked to obesity).[ 5 ]

Recent efforts have shed new light on molecular and cellular circuits linking inflammation and cancer. Two pathways have been schematically identified: in the intrinsic pathway, genetic events causing neoplasia initiate the expression of inflammation-related programs that guide the construction of an inflammatory microenvironment, and in the extrinsic pathway, inflammatory conditions facilitate cancer development.[ 6 ]

The triggers of chronic inflammation that increase cancer risk or progression include infections (e.g., Helicobacter pylori for gastric cancer and mucosal lymphoma; papillomavirus and hepatitis viruses for cervical and liver carcinomas, respectively), autoimmune diseases (e.g., inflammatory bowel disease for colon cancer), and inflammatory conditions of uncertain origin (e.g., prostatitis for prostate cancer). Cancer-related inflammation, the seventh hallmark of cancer, links to genetic instability.[ 7 ]

It was in 1863 that Rudolf Virchow noted leukocytes in neoplastic tissues and made a connection between inflammation and cancer. He suggested that the “lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic inflammation. Over the past 10 years, our understanding of the inflammatory microenvironment of malignant tissues has supported Virchow's hypothesis, and the links between cancer and inflammation are starting to have implications for prevention and treatment.[ 8 ]

I NFLAMMATION AND C AUSES

Inflammation is the body's response to tissue damage, caused by physical injury, ischemic injury (caused by an insufficient supply of blood to an organ), infection, exposure to toxins, or other types of trauma. The body's inflammatory response causes cellular changes and immune responses that result in repair of the damaged tissue and cellular proliferation (growth) at the site of the injured tissue. Inflammation can become chronic if the cause of the inflammation persists or certain control mechanisms in charge of shutting down the process fail. When these inflammatory responses become chronic, cell mutation and proliferation can result, often creating an environment that is conducive to the development of cancer. The so-called “perfect storm” is an extreme challenge that cancer patients face. This is true for the onset of cancer but also even more important for the advancement of the disease. Various signaling pathways are key contributors in creating epigenetic changes on the outside of the cell, switching on these internal mutations. Therefore, treating the inflammatory causes is always important.

Chronic inflammation has been linked to various steps involved in tumorigenesis, including cellular transformation, promotion, survival, proliferation, invasion, angiogenesis, and metastasis.

C ANCER D EVELOPMENT : A N O VERVIEW

Cancer defines malignant neoplasms characterized by metastatic growth. It may occur in almost every organ and tissue relating to a variety of etiologic factors, such as genomic instability and environmental stress.[ 9 ]

However, cancer development is still accepted as a multistep process, during which genetic alterations confer specific types of growth advantages; therefore, it drives the progressive transformation from normal cells to malignant cancer cells. Malignant growth is characterized by several key changes: self-sufficiency of growth signals, insensitivity to antigrowth signals, escaping from apoptosis, unregulated proliferation potential, enhanced angiogenesis, and metastasis. Each of these shifts is complicated and accomplished by combined efforts of various signaling processes. In later discussion, we will find that inflammation may contribute to the formation of these cancer phenotypes.[ 10 ]

M ECHANISMS FOR THE A SSOCIATION BETWEEN I NFLAMMATION AND C ANCER

Chronic inflammation is characterized by sustained tissue damage, damage-induced cellular proliferation, and tissue repair. Cell proliferation in this context is usually correlated with “metaplasia,” a reversible change in cell type. “Dysplasia,” a disorder of cellular proliferation leading to atypical cell production, follows and is regarded as the previous event of carcinoma because it was usually found adjacent to the site of neoplasm.[ 11 ]

M UTAGENIC P OTENTIAL OF I NFLAMMATION

The chronic inflammatory microenvironment is predominated by macrophages. Those macrophages, together with other leukocytes, generate high levels of reactive oxygen and nitrogen species to fight infection.[ 12 ] However, in a setting of continuous tissue damage and cellular proliferation, the persistence of these infection-fighting agents is deleterious. They may produce mutagenic agents, such as peroxynitrite, which react with DNA and cause mutations in proliferating epithelial and stroma cells. Macrophages and T-lymphocytes may release tumor necrosis factor-alpha (TNF-α) and macrophage migration inhibitory factor to exacerbate DNA damage.[ 13 ]

Migration inhibitory factor impairs p53-dependent protective responses, thus causing the accumulation of oncogenic mutations. Migration inhibitory factor also contributes to tumorigenesis by interfering Rb-E2F pathway.

H ELICOBACTER P YLORIAND AND C ANCER R ISK

The bacterium H. pylori is known to colonize the human stomach and induce chronic atrophic gastritis, intestinal metaplasia, and gastric cancer. H. pylori infection is a major risk factor for gastric cancer development, which is one of the most challenging malignant diseases worldwide with limited treatments.[ 14 ]

The multistep pathogenesis of gastric cancer is the best highlighted by Correa sequence that explains the progressive pathway to gastric cancer characterized by distinct histological changes. This model predicts that infection with H. pylori triggers an inflammatory response resulting in chronic, and then, atrophic, gastritis. This is followed by intestinal metaplasia which can be further classified into complete and incomplete subtypes. At this point, some patients will then proceed to gastric cancer via the intermediate stage of dysplasia [ Figure 2 ].[ 15 ]

An external file that holds a picture, illustration, etc.
Object name is AAM-18-121-g002.jpg

Correa sequence

The improvement or elimination of atrophy and intestinal metaplasia with H. pylori eradication could potentially inhibit gastric carcinogenesis. It is noteworthy to mention that gastric cancer can still develop even after successful eradication therapy. H. pylori eradication does not result in the regression of all precancerous lesions, which may depend on the degree and extent of preneoplastic changes at the time of eradication.[ 14 ]

I NFLAMMATORY C ELLS IN T UMOR M ICROENVIRONMENT

The inflammatory microenvironment of tumors is characterized by the presence of host leukocytes both in the supporting stroma and in tumor areas.[ 16 ] Tumor-infiltrating lymphocytes may contribute to cancer growth and spread and to the immunosuppression associated with malignant disease.

Macrophages

Tumor-associated macrophages (TAM) are a major component of the infiltrate of most, if not all tumors. TAM derives from circulating monocytic precursors and is directed into the tumor by chemoattractant cytokines called chemokines. Many tumor cells also produce cytokines called colony-stimulating factors that prolong the survival of TAM. When appropriately activated, TAM can kill tumor cells or elicit tissue destructive reactions centered on the vascular endothelium. However, TAM also produces growth and angiogenic factors as well as protease enzymes which degrade the extracellular matrix. Hence, TAM can stimulate tumor cell proliferation, promote angiogenesis, and favor invasion and metastasis.[ 17 ]

Dendritic cells

Dendritic cells have a crucial role in both the activation of antigen-specific immunity and the maintenance of tolerance, providing a link between innate and adaptive immunity. Tumor-associated dendritic cells (TADCs) usually have an immature phenotype with defective ability to stimulate T-cells.[ 18 ]

This distribution of TADC is clearly different from that of TAM, which is evenly scattered in tumor tissue. The immaturity of TADC may reflect lack of effective maturation signals, prompt migration of mature cells to lymph nodes, or the presence of maturation inhibitors. TADC is likely to be poor inducers of effective responses to tumor antigens.

Lymphocytes

Natural killer cells are rare in the tumor microenvironment. The predominant T-cell population has a “memory” phenotype. The cytokine profile of these tumor-infiltrating T-cells has not been studied systematically, but in some tumors (e.g. Kaposi's sarcoma, Hodgkin's disease, bronchial carcinoma, and cervical carcinoma), they produce mainly interleukins (ILs) 4 and 5 and not interferon. IL-4 and 5 are cytokines associated with the T-helper type 2 (Th2) cells, whereas interferon is associated with Th1 responses.[ 19 ]

K EY M OLECULAR P LAYERS IN L INKING I NFLAMMATION TO C ANCER

To address the details of transition from inflammation to cancers and the further development of inflammation-associated cancers, it is necessary to investigate specific roles of key regulatory molecules involved in this process.

Pro-inflammatory cytokines

The cytokine network of several common tumors is rich in inflammatory cytokines, growth factors, and chemokines but generally lacks cytokines involved in specific and sustained immune responses.[ 20 ]

There is now evidence that inflammatory cytokines and chemokines, which can be produced by the tumor cells and/or tumor-associated leukocytes and platelets, may contribute directly to malignant progression. Many cytokines and chemokines are inducible by hypoxia, which is a major physiological difference between tumor and normal tissue. Examples are TNF, IL-1 and 6, and chemokines.

The immune response to tumors is constituted by cytokines produced by tumor cells as well as host stromal cells. Tumor-derived cytokines, such as Fas ligand, vascular endothelial growth factor (VEGF), and transforming growth factor-h, may facilitate the suppression of immune response to tumors. Moreover, inflammatory cytokines have also been reported to facilitate the spectrum of tumor development.[ 21 ]

Tumor necrosis factor

TNF is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated carcinogenesis. TNF exerts its biological functions through activating distinct signaling pathways such as nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK). NF-κB is a major cell survival signal that is antiapoptotic while sustained JNK activation contributes to cell death. The crosstalk between the NF-κB and JNK is involved in determining cellular outcomes in response to TNF. TNF is a double-edged sword that could be either pro- or antitumorigenic. On one hand, TNF could be an endogenous tumor promoter because TNF stimulates cancer cells' growth, proliferation, invasion and metastasis, and tumor angiogenesis. On the other hand, TNF could be a cancer killer. The property of TNF in inducing cancer cell death renders it a potential cancer therapeutic.[ 22 ]

TNF can be detected in malignant and/or stromal cells in human ovarian, breast, prostate, bladder, and colorectal cancer, lymphomas, and leukemias, often in association with ILs-1 and 6 and macrophage colony-stimulating factor.[ 23 ]

Interleukins 1 and 6 in cancer regulation

IL-6 is a pleiotropic cytokine that plays important roles in immune response, inflammation, and hematopoiesis. It is produced by a variety of normal cells including monocytes and macrophages but is also expressed by multiple tumor tissue types, such as breast, prostate, colorectal, and ovarian cancer. IL-6 may also play an important role in various aspects of tumor behavior, including apoptosis, tumor growth cell proliferation, migration and invasion, angiogenesis, and metastasis.[ 24 ]

IL-10, initially termed “cytokine synthesis inhibitor” or “cytokine inhibitory factor” due to its inhibitory action on cytokine production by T helper cells, is produced by almost all leukocytes, as well as numerous human tumor cells including breast, kidney, colon, pancreas, malignant melanomas, and neuroblastomas. IL-10 is essential to suppress tumor-promoting inflammation mediators, thereby facilitating tumor growth and metastasis. Specifically, TAMs produce IL-10 and are also associated with in-tumor immunosuppression, thereby providing a suitable microenvironment for cancer growth.[ 25 ]

In mouse models of metastasis, treatment with an IL-1 receptor antagonist (which inhibits the action of IL-1) significantly decreased tumor development, suggesting that local production of this cytokine aids the development of metastasis. Moreover, mice deficient in IL-1 were resistant to the development of experimental metastasis.[ 26 ]

Inflammatory cytokines are major inducers of a family of chemoattractant cytokines called chemokines that play a central role in leukocyte recruitment to sites of inflammation. Most tumors produce chemokines of the two major groups α (or CXC) and β.

Typically, CXC chemokines are active on neutrophils and lymphocytes, whereas CC chemokines act on several leukocyte subsets including monocytes, eosinophils, dendritic cells, lymphocytes, and natural killer cells but not neutrophils.[ 27 ]

Human and murine tumors also frequently secrete CXC chemokines such as IL-8. These chemokines are potent neutrophil attractants, yet neutrophils are rare in tumors. However, both IL-8 and a related chemokine called “gro” induce proliferation and migration of melanoma cell.

I MPLICATIONS FOR P REVENTION AND T REATMENT

Tumor necrosis factor blockade.

TNF antagonists (etanercept [Enbrel] and infliximab [Remicade]) have been licensed for a clinical trial in the treatment of rheumatoid arthritis and Crohn's disease, with over 70,000 patients now treated. Thalidomide inhibits the processing of mRNA for TNF and VEGF, and continuous low-dose thalidomide has shown activity in patients with advanced myeloma. The role of etanercept in ameliorating the adverse effects of other cancer therapies is also being evaluated. There are also ongoing and planned clinical trials with infliximab. As with other “biological” approaches to cancer treatment, anti-TNF therapy may be optimal in an adjuvant setting with minimal disease.[ 28 ]

Chemokine antagonism

Chemokine receptors belong to a family of receptors (transmembrane G-protein-coupled receptors) which is already a target of pharmacological interest. Tumors driven by chemokines and those where chemokines are implicated in metastasis (e.g. seeding to lymph nodes) may be an appropriate target for chemokine antagonists now under development.[ 29 ]

IL-6 is a major growth factor for myeloma cells. In advanced disease, there is an excess of IL-6 production, and raised serum concentrations are associated with plasmablastic proliferative activity and short survival.

Nonsteroidal anti-inflammatory agents

Nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective or selective COX-1/2 inhibitors, which are wildly prescribed for pain killing, fever reduction, and even anti-inflammation.

Patients on NSAIDs are at reduced risk of colon cancer. This may also be true for cancers of the esophagus, stomach, and rectum, and in rodents experimental bladder, breast, and colon cancer. Colon cancer is reduced when NSAIDs are administered concurrently with carcinogens. NSAIDs inhibit cyclooxygenase enzymes and angiogenesis.[ 30 ]

The mechanisms involved in the association between NSAIDs and distant metastasis inhibition remain incompletely investigated. One possible explanation is that NSAIDs inhibit COX2. Abnormally high COX2 expression is observed in multicancers. Disordered COX2/PGE pathway is involved in multicancer processes, including carcinogenesis, proliferation, and metastatic spread; in addition, inhibition of COX2/PGE pathway with NSAIDs can restrain cancer cell lines.

Mutual promotion relationship between cancer metastasis and cancer-associated thrombosis is possibly another one of the underlying mechanisms. Abnormally high constitutive level of tissue factor (TF), one key regulator of hemostasis, is expressed by metastatic cancer cells, cancer microparticles, and cancer-associated monocytes and macrophages. TF can promote thrombosis formation by activating the extrinsic pathway of coagulation cascade. Furthermore, inflammation induced by thrombosis could result in endothelial damage that results in the vascular leak, facilitating the escape of cancer cells from blood vessels. Consequently, NSAIDs may disrupt the relationship between cancer metastasis and cancer-associated thrombosis via the suppression of platelet function, which is detrimental for the disseminated cancer cells in the bloodstream.[ 31 ]

C ONCLUSION

Overall, this review provides evidence for a strong link between chronic inflammation and cancer. Thus, inflammatory biomarkers as described here can be used to monitor the progression of the disease. These biomarkers can also be exploited to develop new anti-inflammatory drugs to prevent and treat cancer. These drugs can also be used as an adjuvant to the currently available chemotherapy and radiotherapy, which by themselves activate NF-κB and mediate resistance. Numerous anti-inflammatory agents including those identified from natural sources have been shown to exhibit chemopreventive activities.

Financial support and sponsorship

Conflicts of interest.

There are no conflicts of interest.

R EFERENCES

Treatment Research

In a clinical trial, people being treated for cancer who participated in virtual mind–body fitness classes were less likely to be hospitalized, and had shorter stays when they were hospitalized, than people who did not take the classes.

NCI’s James H. Doroshow, M.D., reflects on the accomplishments of NCI-MATCH, a first-of-its-kind precision medicine cancer trial, and gives an overview of three new successor trials: ComboMATCH, MyeloMATCH, and iMATCH.

A new study, conducted largely in mice, may help explain why a currently used molecular marker—called mismatch repair deficiency—doesn’t always work to predict which patients will respond to immunotherapies called immune checkpoint inhibitors.

New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.

A cancer-infecting virus engineered to tamp down a tumor’s ability to suppress the immune system shrank tumors in mice, a new study shows. The modified oncolytic virus worked even better when used along with an immune checkpoint inhibitor.

Despite recommendations, a new analysis shows few people with cancer undergo germline testing to learn if their cancer may have been caused by gene changes inherited from a parent. Germline testing can help doctors determine the best treatments for a patient and help identify people whose family members may be at higher risk of cancer.

ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.

A new study has compared three formulations of an mRNA vaccine designed to treat cancers caused by human papillomavirus (HPV) infections. All three vaccines showed promise in mice.

Researchers have identified a mechanism by which cancer cells develop specific genetic changes needed to become resistant to targeted therapies. They also showed that this process, called non-homologous end-joining (NHEJ), can potentially be disrupted.

For some people with cancer, is 6 months of immunotherapy the only treatment they might ever need? Or 4 weeks of immunotherapy followed by minor surgery? Results from several small clinical trials suggest these scenarios may be bona fide possibilities.

Two research teams have developed ways of overcoming barriers that have limited the effectiveness of CAR T-cell therapies, including engineering ways to potentially make them effective against solid tumors like pancreatic cancer and melanoma.

In people with cancer treated with immune checkpoint inhibitors, a rare, but often fatal, side effect is inflammation in the heart, called myocarditis. Researchers have now identified a potential chief cause of this problem: T cells attacking a protein in heart cells called α-myosin.

Researchers have modified a chemo drug, once abandoned because it caused serious gut side effects, so that it is only triggered in tumors but not normal tissues. After promising results in mice, the drug, DRP-104, is now being tested in a clinical trial.

Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.

Inflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.

NCI researchers are developing an immunotherapy that involves injecting protein bits from cytomegalovirus (CMV) into tumors. The proteins coat the tumor, causing immune cells to attack. In mice, the treatment shrank tumors and kept them from returning.

FDA has approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for nearly any type of advanced solid tumor with a specific mutation in the BRAF gene. Data from the NCI-MATCH trial informed the approval.

People with cancer who take immunotherapy drugs often develop skin side effects, including itching and painful rashes. New research in mice suggests these side effects may be caused by the immune system attacking new bacterial colonies on the skin.

Researchers have developed tiny “drug factories” that produce an immune-boosting molecule and can be implanted near tumors. The pinhead-sized beads eliminated tumors in mice with ovarian and colorectal cancer and will soon be tested in human studies.

Women are more likely than men to experience severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, a new study finds. Researchers hope the findings will increase awareness of the problem and help guide patient care.

Research to improve CAR T-cell therapy is progressing rapidly. Researchers are working to expand its use to treat more types of cancer and better understand and manage its side effects. Learn how CAR T-cell therapy works, which cancers it’s used to treat, and current research efforts.

Experts say studies are needed on how to best transition telehealth from a temporary solution during the pandemic to a permanent part of cancer care that’s accessible to all who need it.

Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.

A specific form of the HLA gene, HLA-A*03, may make immune checkpoint inhibitors less effective for some people with cancer, according to an NCI-led study. If additional studies confirm the finding, it could help guide the use of these commonly used drugs.

The success of mRNA vaccines for COVID-19 could help accelerate research on using mRNA vaccine technology to treat cancer, including the development of personalized cancer vaccines.

Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells, but scientists didn’t know why. Two new studies suggest that aneuploidy helps the cells survive treatments like chemotherapy and targeted therapies.

New research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found.

FDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.

In lab studies, the antibiotic novobiocin showed promise as a treatment for cancers that have become resistant to PARP inhibitors. The drug, which inhibits a protein called DNA polymerase theta, will be tested in NCI-supported clinical trials.

A drug called avasopasem manganese, which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests.

While doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.

Cholesterol-lowering drugs known as PCSK9 inhibitors may improve the effectiveness of cancer immune checkpoint inhibitors, according to studies in mice. The drugs appear to improve the immunotherapy drugs’ ability to find tumors and slow their growth.

Researchers have developed a nanoparticle that trains immune cells to attack cancer. According to the NCI-funded study, the nanoparticle slowed the growth of melanoma in mice and was more effective when combined with an immune checkpoint inhibitor.

A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.

Researchers are developing a new class of cancer drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells. This Cancer Currents story explores the research on these emerging therapies.

FDA has recently approved two blood tests, known as liquid biopsies, that gather genetic information to help inform treatment decisions for people with cancer. This Cancer Currents story explores how the tests are used and who can get the tests.

Cancer cells with a genetic feature called microsatellite instability-high (MSI-high) depend on the enzyme WRN to survive. A new NCI study explains why and reinforces the idea of targeting WRN as a treatment approach for MSI-high cancer.

Efforts to contain the opioid epidemic may be preventing people with cancer from receiving appropriate prescriptions for opioids to manage their cancer pain, according to a new study of oncologists’ opioid prescribing patterns.

The gene-editing tool CRISPR is changing the way scientists study cancer, and may change how cancer is treated. This in-depth blog post describes how this revolutionary technology is being used to better understand cancer and create new treatments.

FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

Patients with acute graft-versus-host disease (GVHD) that does not respond to steroid therapy are more likely to respond to the drug ruxolitinib (Jakafi) than other available treatments, results from a large clinical trial show.

NCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the capability to make CAR T cells, which has limited the ability to test them more broadly.

An experimental drug may help prevent the chemotherapy drug doxorubicin from harming the heart and does so without interfering with doxorubicin’s ability to kill cancer cells, according to a study in mice.

In people with blood cancers, the health of their gut microbiome appears to affect the risk of dying after receiving an allogeneic hematopoietic stem cell transplant, according to an NCI-funded study conducted at four hospitals across the globe.

A novel approach to analyzing tumors may bring precision cancer medicine to more patients. A study showed the approach, which analyzes gene expression using tumor RNA, could accurately predict whether patients had responded to treatment with targeted therapy or immunotherapy.

Bone loss associated with chemotherapy appears to be induced by cells that stop dividing but do not die, a recent study in mice suggests. The researchers tested drugs that could block signals from these senescent cells and reverse bone loss in mice.

Some experts believe that proton therapy is safer than traditional radiation, but research has been limited. A new observational study compared the safety and effectiveness of proton therapy and traditional radiation in adults with advanced cancer.

In people with cancer, the abscopal effect occurs when radiation—or another type of localized therapy—shrinks a targeted tumor but also causes untreated tumors in the body to shrink. Researchers are trying to better understand this phenomenon and take advantage of it to improve cancer therapy.

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.

Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.

FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.

A new NCI-supported study showed that altering cancer cell metabolism by feeding mice a diet very low in the nutrient methionine improved the ability of chemotherapy and radiation therapy to shrink tumors.

An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.

Researchers have identified a protein called CD24 that may be a new target for cancer immunotherapy. The protein is a ‘don’t eat me’ signal that prevents immune cells called macrophages from engulfing and eating cells.

Injecting cells undergoing necroptosis, a form of cell death, into tumors in mice kickstarted an immune response against the tumors, researchers have found. When combined with immunotherapy, the treatment was effective at eliminating tumors in mice.

Researchers have identified proteins that may play a central role in transforming T cells from powerful destroyers to depleted bystanders that can no longer harm cancer cells. The findings could lead to strategies for boosting cancer immunotherapies.

Did you know that NCI supports clinical trials of new treatments for pet dogs with cancer? Learn more about NCI’s comparative oncology studies and how they may also help people with cancer.

Researchers have discovered a potential way to turn on one of the most commonly silenced tumor-suppressor proteins in cancer, called PTEN. They also found a natural compound, I3C, that in lab studies could flip the on switch.

New findings from a clinical trial suggest that a single dose of radiation therapy may control painful bone metastases as effectively as multiple lower doses of radiation therapy.

The expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.

The investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.

A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.

Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.

Book cover

Herbs for Cancer Treatment pp 53–150 Cite as

Types of Cancer

  • Bhupendra Koul 2  
  • First Online: 08 January 2020

1264 Accesses

1 Citations

Cancer is an extremely fatal disease, not only in developed but also in developing countries as it affects six million lives each year worldwide. According to the American Cancer Society each year 0.5% of US population is diagnosed with cancer. Annually, billions of dollars are invested on cancer research, yet the success rates are not satisfactory. Cancer cells arise due to the imbalance in the body functions and they invade and infect the normal cells. Cancer is not one disease; rather it is a group of various diseases. The present chapter includes explicit information on cancer types such as cancer of blood, lungs, colon and rectum, prostate, skin, breast, uterus, thyroid, lymphatic system, etc. Cancers are being treated by various methods which include chemotherapy, precision medicine, radiation therapy, surgery, stem cell transplant, hormone therapy, immune therapy, and targeted therapy. In some cases, cancer can be treated by single method, but mostly several methods are used to cure the disease. Moreover, the treatment specifically depends upon the stage and type of cancer. In chemotherapy and radiotherapy, survival rates are usually very low because of their undesirable side effects on human health. On the contrary, herbal therapy alone and in combination with the routine cancer treatment regimes has shown some promising potential, as it is free from side effects.

This is a preview of subscription content, log in via an institution .

Buying options

  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
  • Available as EPUB and PDF
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
  • Durable hardcover edition

Tax calculation will be finalised at checkout

Purchases are for personal use only

Abbas J, Dar WR, Latief M, Farooq S, Parry MA, Ziaulhaq P, Sofi NU, Dar I (2016) Gastrointestinal stromal tumors: a review. J Mol Imag Dynamic 10(4172):2155–9937

Google Scholar  

Abbasi NR (2008) Utility of lesion diameter in the clinical diagnosis of cutaneous melanoma. Arch Dermatol 144:538–540

Advani P, Paulus A, Ailawadhi S (2019) Updates in prognostication and treatment of Waldenström’s macroglobulinemia. Hematology/oncology and stem cell therapy (in press)

Aggarwal A, Lewison G, Idir S, Peters M, Aldige C, Boerckel W, Boyle P, Trimble EL, Roe P, Sethi T, Fox J, Sullivan R (2016) The state of lung cancer research: a global analysis. J Thorac Oncol 11(7):1040–1050

PubMed   Google Scholar  

Albers P, Albrecht W, Algaba F (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068

Ali MZ, Sultana S (2012) Blood cancer. Bangladesh Research Institute 221:4303–4602

Ali I, Wani WA, Saleem K (2011) Cancer scenario in India with future perspectives. Cancer Ther 8:56–70

American Cancer Society. (2015) Cancer facts and figures

American Cancer Society, 2017, USA

Anjum F, Ravi N, Msood MA (2017) Breast cancer therapy: a mini review. MOJ Drug Des Dev Ther 1(2):00006

Babjuk M, Böhle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461

Banumathy G, Cairns P (2010) Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10:658–664

CAS   PubMed   PubMed Central   Google Scholar  

Bãrbuş E, Peştean C, Larg MI, Piciu D (2017) Quality of life in thyroid cancer patients: a literature review. Clujul Med 90(2):147–153

PubMed   PubMed Central   Google Scholar  

Bermick (2008) Are tanning beds “safe”. Human studies of melanoma. Pigment Cell Melanoma Res 21(5):517–519

Blackadar CB (2016) Historical review of the causes of cancer. World J Clin Oncol 7(1):54–86

Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564

CAS   PubMed   Google Scholar  

Chng WJ, Glebov O, Bergsagel PL (2007) Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haemotal 20(4):571–596

CAS   Google Scholar  

Chou J, Lin Y, Kim J, You L, Xu Z (2017) Nasopharyngeal carcinoma– a review of the molecular mechanisms of tumorigenesis. Head Neck 30(7):946–963

Coimbra S, Neves R, Lima M, Belo L, Silva AS (2014) Waldenstrom’s macroglobulinemia review. Rev Assoc Med Bras 60(5):490–499

Cserni G, Chmielik E, Cserni B, Tot T (2018) The new TNM-based staging of breast cancer. Virchows Arch 472(5):697–703

Finicle BT, Jayashankar V, Edinger AL (2018) Nutrient scavenging in cancer. Nat Rev Cancer 18:619–633

Flis S, Chojnacki T (2019) Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther 13:825–843

Fu JH, Rong TH, Li XD, Hu V, Ou W, Hu YH, Li Q (2004) Chemotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial. Ai Zheng 23(11):1473–1476

Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphogenic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663

Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I, Briganti A, Karakiewicz PI, Trinh QD, Jewett MA, Sun M (2014) Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 8:247–252

Gertz MA (2019) Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 94(2):266–276

GLOBOCAN (2012) v1.0, cancer incidence and mortality worldwide: IARC Cancer Base no. 11. International Agency for Research on Cancer Web site. http://globocan.iarc.f

Goblirsch MJ, Zwolak PP, Clohisy DR (2006) Biology of bone Cancer pain. Clin Cancer Res 12:6231s–6235s

Gogoi G, Borgohain M, Saikia P, Patel B, Hazauka RK, Brahma RC, Gogoi B, Saikia N, Rabha J (2017) Histomorphological study of soft tissue tumours and review of literature of rarer types. Int Clin Pathol J 4:00113–00123

Gubbels JAA, Claussen N, Kapur AK, Connor JP, Patankar MS (2010) The detection, treatment and biology of epithelial ovarian cancer. J Ovarian Res 3(8):1757–2215

Hartman RI, Lin JY (2019) Cutaneous melanoma-a review in detection, staging, and management. Hematol Oncol Clin North Am 33(1):25–38

Heitz APM, Odicino F, Maisonneuva P, Quinn MA, Benedet JL, Creasmam WT, Ngan HYS, Pecorelli S, Beller U (2006) Carcinoma of the ovary. Intituto Europeo di Oncologia 95(1):60033–60037

Hoang NT, Acevedo LA, Mann MJ, Tolani B (2018) A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res 10:1089–1114

http://cancerwall.com

Huang S (2018) Physical activity and risk of testicular cancer-a systematic review. BMC Cancer 18(1):189

Ivanyi P, Fuehner T, Adam M, Eichelberg C, Herrmann E, Merseburger AS, Ganser A, Grunwald V (2014) Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. Med Oncol 31:147

Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459

Jaggi P (2017) A review article on lung cancer diagnosis and treatment. JMAHS 6(1):2318–9865

Jarmusch AK, Pirro V, Baird Z, Hattab EM, Cooks G (2016) Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization. MS PNAS 113(6):1486–1419

Kamoun W, Elden S, Christine P, Lia L, Jason C, Irawati K, Richard H (2018) Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic. Am Assoc Cancer Res 78(13):5771–5771

Karst AM, Drapkin R (2010) Ovarian cancer pathogenesis: a model of evolution. J Oncol 10:93237

Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH (2016) Oncogenic roles of TOPK and MELK and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget 7(14):17652

Khaider NG, Lane D, Matte I, Rancourt C, Piche A (2011) Targeted ovarian cancer treatment: the TRAILs of resistance. AMJ Cancer Res 2(1):75–92

Kirkali Z, Canda AE (2008) Open partial nephrectomy in the management of small renal masses. Adv Urol 309760

Kirkali Z, Tuzel E, Mungan MU (2001) Recent advances in kidney cancer and metastatic disease. BJU Int 88(8):818–824

Kotz R, Dominkus M, Zettl T, Ritschl P, Windhager R, Gadner H, Zielinski C, Salzer-Kuntschik M (2002) Advances in bone tumour treatment in 30 years with respect to survival and limb salvage. A single institution experience. Int Orthop 26(4):197–202

Lai JS, Beaumont JL, Diaz J, Khan S, Cella D (2016) Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer 122:287–295

Laura H (2016) Hodgkin’s disease and lymphoma. Am Cancer Soc 32(7):34–42

Laws ER Jr, Thapar K (1993) Brain tumors. CA Cancer J Clin 43:263–271

Layke JC, Lopez PP (2006) Esophageal cancer: a review and update. Am Fam Physician 73:2187–2194

Leitzmann MF, Rohrmann S (2012) Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 4:1–11

Lin JS, Bowles EJ, Williams SB, Morrison CC (2017) Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 31:888–903

Ljungberg B, Bensalah K, Bex A et al (2014) Guidelines on renal cell carcinoma. European Association of Urology. Available at https://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_2017_web.pdf

Lorsbach RB, His ED, Dogan A, Fend F (2011) Plasma cell myeloma and related neoplasm. Am J Clin Pathol 136(2):168–182

Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61(10):4038–4047

Magalhaes KCS, Vaz JPM, Gontijo PAM, Carvalho GTC, Christo PP, Simoes RT, Silva KR (2016) Profile of patients with brain tumors and tumors and the role of nursing care. Rev Bras Enferm 69(1):138–143

Maguire R, Andelkovic V, Chauhan H, Nolan GJ (2017) Advances in the management of soft tissue sarcomas- focus on emerging therapies. Clin Oncol 2:1189–1196

Marnouche E (2017) Diagnosis, therapeutic and evolutionary characteristics of nasopharyngeal Cancer in Morocco. J Cancer Sci Ther 9:439–444

Martínez-Carmona M, Lozano D, Baeza A, Colilla M, Vallet-Regí M (2018) A novel visible light responsive nanosystem for cancer treatment. Nanoscale 9(41):15967–15973

Miranda MB, Leusekes M, Kraus MP, Hanftein B, Fabarin A, BAerloches GM (2016) Secondary malignancies in chronic myeloid leukemia patients after imatinib based treatment: long term observation. Leukemia 30(6):1255–1262

Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K (2006) Diagnosis of pancreatic cancer. HPB (Oxford) 8(5):337–342

Moore K, Kim L (2010) Primary brain tumors: characteristics practical diagnostic and treatment approaches. Molecular mechanism of pathogenesis and current therapeutic strategies 10:42–75

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, Santis MD, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629

Muglia VF, Prando A (2015) Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 48(3):166–174

National Comprehensive Cancer Network. Guidelines for patients version 1, 2016

National Comprehensive Cancer Network. Guidelines for patients 2017

Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58:588–595

Paek SC (2008) Cutaneous melanomas. Fitzpatrick’s Dermatology in General Medicine 109(1):100–108

Paladini A, Boni A, Quadrini F, Cochetti G, Mearini E (2017) First report of simultaneous robotic treatment of kidney cancer and enucleation of pancreatic metastasis. Eur Uro 16(6):2385

Patil M, Prabhu S, Patil S, Patil S (2013) Brain tumor identification using K–means clustering. IJETT 4(3):354–357

Permutt WJ, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413–437

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R (2011) External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 186:1773–1777

Pokharel M (2012) Leukemia a review article. Leukemia IJARP 2(3):397–407

Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non–small cell lung cancer. N Engl J Med 377:849–861

Roett MA, Evans P (2009) Ovarian cancer: an overview. Am Fam Physician 80(6):609–616

Salati SA, Al Kadi A (2012) Anal cancer. Int J Cancer Health Sci 6(2):206–230

Schmidbauer B, Menhart K, Hellwig D, Grosse J (2017) Differentiated thyroid Cancer-treatment: state of the art. Int J Mol Sci 18(6):1292

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30

Son SH, Song JH, Choi BO et al (2012) The technical feasibility of an image-guided intensity-modulated radiotherapy (IGIMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer. Radiat Oncol 7, Article 203

Stolzoff M, Webster TJ (2016) Reducing bone cancer cell functions using selenium nanocomposites. J Biomed Mater Res 104:476–482

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111:1909–1916

Wan J, Li XM, Gu J (2014) Primary Choriocarcinoma of the fallopian tube: a case report and literature review. Eur J Gynaecol Oncol 35(5):604–607

Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW (2001) Ultraviolet a and melanoma: a review. J Am Acad Dermatol 44:837–846

Weinberg RA (2014) The biology of cancer, 2nd edn

Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J (2016) mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int J Cancer 138:2312–2321

Winkler T, Sass FA, Duda GN, Schmidt-Bleek K (2018) A review of biomaterials in bone defect healing, remaining shortcomings and future opportunities for bone tissue engineering: the unsolved challenge. Bone Joint Res 7(3):232–243

Wong R, Malthaner R (2006) Combined chemotherapy and radiotherapy. Cochrane Database Syst Rev 1:CD002092

Wuellner L (2014) Understanding brain tumours. Cancer Council NSW 54(12):134–164

www.cancer.net (2017)

www.cancer.org National Cancer Institute, 2018

www.medicinenet.com

www.rightdiagnosis.com

www.webmd.com

Yamamoto E (2009) Ovary: choriocarcinoma. Atlas genet. Cytogenet Oncol Haematol 13(9):683–685

Yaxley JP (2016) Bladder cancer. J Family Med Prim Care 5(3):533–538

Yeole BB (2008) Trends in the brain cancer incidence in India. Asian Pac J Cancer Prev 9(2):267–270

Yoo KY, Shin HR (2003) Cancer epidemiology and prevention. Korean J Epidemiol 25:1–15

Zotos D, Taclinton D (2012) Determining B-cell fate. Trends Immunol 33(6):280–288

Zujewski JA, Harlan LC, Morrell DM, Stevens JL (2011) Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat 127(1):251–257

Download references

Author information

Authors and affiliations.

Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India

Bhupendra Koul

You can also search for this author in PubMed   Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter.

Koul, B. (2019). Types of Cancer. In: Herbs for Cancer Treatment. Springer, Singapore. https://doi.org/10.1007/978-981-32-9147-8_2

Download citation

DOI : https://doi.org/10.1007/978-981-32-9147-8_2

Published : 08 January 2020

Publisher Name : Springer, Singapore

Print ISBN : 978-981-32-9146-1

Online ISBN : 978-981-32-9147-8

eBook Packages : Biomedical and Life Sciences Biomedical and Life Sciences (R0)

Share this chapter

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

  • Publish with us

Policies and ethics

  • Find a journal
  • Track your research
  • Open access
  • Published: 04 December 2020

RNA sequencing: new technologies and applications in cancer research

  • Mingye Hong 1   na1 ,
  • Shuang Tao 2   na1 ,
  • Ling Zhang 3 ,
  • Li-Ting Diao 2 ,
  • Xuanmei Huang 1 ,
  • Shaohui Huang 1 ,
  • Shu-Juan Xie 2 ,
  • Zhen-Dong Xiao 2 &
  • Hua Zhang   ORCID: orcid.org/0000-0001-9731-2737 1  

Journal of Hematology & Oncology volume  13 , Article number:  166 ( 2020 ) Cite this article

59k Accesses

185 Citations

27 Altmetric

Metrics details

Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing to single-molecular, single-cell and spatial transcriptome approaches has enabled increasingly accurate, individual cell resolution incorporated with spatial information. Cancer, a major malignant and heterogeneous lethal disease, remains an enormous challenge in medical research and clinical treatment. As a vital tool, RNA sequencing has been utilized in many aspects of cancer research and therapy, including biomarker discovery and characterization of cancer heterogeneity and evolution, drug resistance, cancer immune microenvironment and immunotherapy, cancer neoantigens and so on. In this review, the latest studies on RNA sequencing technology and their applications in cancer are summarized, and future challenges and opportunities for RNA sequencing technology in cancer applications are discussed.

Cancer remains one of the major malignant diseases that endangers human life and health and comprises complex biological systems that require accurate and comprehensive analysis. Since the first appearance of high-throughput sequencing in 2005 [ 1 ], it has become possible to understand life activities at the molecular level and to conduct detailed research to elucidate the genome and transcriptome. As an essential part of high-throughput sequencing, RNA sequencing (RNA-seq), especially single-cell RNA sequencing (scRNA-seq), provides biological information on a single tumor cell, analyzes the determinants of intratumor expression heterogeneity and identifies the molecular basis of formation of many oncological diseases [ 2 , 3 ]. Thus, RNA sequencing offers invaluable insights for cancer research and treatment. With the advent of the era of precision medicine, RNA sequencing will be widely used for research on many different types of cancer. This review summarizes the history of the development of RNA sequencing and focuses on the latest studies of RNA sequencing technology in cancer applications, especially single-cell RNA sequencing and spatial transcriptome sequencing. In addition, we provide a general introduction to the current bioinformatics analysis tools used for RNA sequencing and discuss future challenges and opportunities for RNA sequencing technology in cancer applications.

The development of RNA sequencing technologies

It was not until 1953 when Watson and Crick proposed the double-helix structure did people truly realize at the molecular level that the essence of life is the result of gene interactions [ 4 ]. The continuous development of RNA sequencing has ushered transcriptome analysis into a new era, with higher efficiency and lower cost. The timeline of RNA sequencing technologies is shown in Fig.  1 .

figure 1

The development timeline of RNA sequencing technologies

The first-generation sequencing technology is also called Sanger sequencing. The chain termination method was initiated by Sanger in 1977, followed by the chemical degradation method developed by Maxam and Gilbert [ 5 , 6 ]. The same year, Sanger determined the 5368 bp genome of phage φX174, which is the first DNA genome sequenced [ 7 ]. The DNA microarray has aided significant progress in many fields since it was first introduced. However, microarrays require prior knowledge of gene sequences and are unable to identify novel gene expression [ 8 ]. After the first high-throughput sequencing platform appeared in 2005 [ 1 ], multiple next-generation sequencing platforms followed (Table 1 , Figs.  2 , 3 ). The accuracy and reproducibility among different platforms depended on several factors, including the inherent features of the platform and the corresponding analysis pipelines [ 9 , 10 ]. Pyrosequencing that was no longer supported after 2016, developed by 454 Life Sciences, used a “sequencing by synthesis” method [ 1 , 11 , 12 , 13 ]. The ion torrent sequencing platform is also based on the “sequencing by synthesis” method, which outperforms pyrosequencing with respect to sensitivity. SOLiD (Sequencing by Oligonucleotide Ligation and Detection) exhibits high accuracy, as each base is sequenced twice, but the read length is short [ 11 , 12 , 13 ]. DNBS (DNA nanoball sequencing) enables large collection of DNA nanoballs for simultaneous sequencing. Illumina-based sequencing technology represents a “reversible terminator sequencing” method. High-throughput sequencing has the advantage of fast speed, low sequencing cost and high accuracy, otherwise known as next-generation sequencing (NGS). Compared to microarray, it can detect unknown gene expression sequences but is time intensive [ 14 ].

figure 2

RNA extraction and template preparation before RNA-sequencing. RNA was extracted from tissues, and after fragmentation, fragmented DNA molecules were converted into cDNA by reverse transcription then amplified by emulsion PCR or bridge PCR to prepare sequencing library

figure 3

Three kinds of sequencing methods. These methods contain sequencing by synthesis, sequencing by reversible terminator and sequencing by ligation. And their different mechanisms are shown in detail

In addition to NGS, there is third-generation sequencing, which allows for long-read sequencing of individual RNA molecules [ 15 ]. Single-molecule RNA sequencing enables the generation of full-length cDNA transcripts without clonal amplification or transcript assembly. Thus, third-generation sequencing is free from the shortcomings generated by PCR amplification and read mapping. It can greatly reduce the false positive rate of splice sites and capture the diversity of transcript isoforms [ 15 ]. Single-molecule sequencing platforms comprise Pacific Biosciences (PacBio) single-molecule real-time (SMRT) sequencing [ 16 ], Helicos single-molecule fluorescent sequencing [ 17 ] and Oxford Nanopore Technologies (ONT) nanopore sequencing [ 18 ]. Furthermore, RNA-seq recently evolved from bulk sequencing to single-cell sequencing. Single-cell RNA sequencing was first published in 2009 to profile the transcriptome at single-cell resolution [ 19 ]. Drop-Seq and InDrop were initially reported in 2015 by analyzing mouse retina cell and embryonic stem cell transcriptomes, identifying novel cell types. Sci-RNA-seq, single-cell combinatorial indexing RNA sequencing, was developed in 2017, and SPLiT-seq (split-pool ligation-based transcriptome sequencing) was first reported in 2018. Both approaches use a combinatorial indexing strategy in which attached RNAs are labeled with barcodes that indicate their cellular origin [ 20 , 21 ].

Though single-cell data enable single-cell transcriptomics, it may lose spatial information during single-cell isolation. To solve this problem, spatial transcriptomics has emerged. Spatial transcriptomics employs unique positional barcodes to visualize RNA distributions in RNA sequencing of tissue sections and was first published in 2016 [ 22 ]. Slide-seq, reported in 2019, uses DNA barcode beads with specific positional information [ 23 ]. Geo-seq was introduced in 2017 and integrated scRNA-seq with laser capture microdissection (LCM), which can isolate individual cells [ 24 ]. In situ sequencing refers to targeted sequencing of RNA fragments in morphologically preserved tissues or cells without RNA extraction, including in situ cDNA synthesis by padlock probes or stably cross-linked cDNA amplicons in fluorescent in situ RNA sequencing (FISSEQ) and in situ amplification by rolling-circle amplification (RCA) [ 25 , 26 ]. Furthermore, various new technologies based on RNA-seq have been developed for specific applications. For example, a type of targeted RNA sequencing, CaptureSeq, employs biotinylated oligonucleotide probes and results in the enrichment of certain transcripts to identify gene fusion [ 27 , 28 ].

Computational analysis of RNA sequencing data

Computational analysis tools for RNA sequencing have dramatically increased during the past decade. The choice of a particular tool should be based on the purpose and accuracy of application [ 29 , 30 , 31 ]. A general RNA sequencing data analysis process involves the quality control of raw data, read alignment and transcript assembly, expression quantification and differential expression analysis (Fig.  4 ).

figure 4

Bioinformatics tools commonly used in RNA-seq data analysis. These tools are primarily used in the four main processes of RNA-seq data analysis, including quality control, read alignment and transcript assembly, expression quantification and differential expression analysis

The first step of data analysis is to assess and clean the raw sequencing data, which is usually provided in the form of FASTQ files [ 32 ]. Quality control visually reflects the quality of the sequencing and purposefully discards low-quality reads, eliminates poor-quality bases and trims adaptor sequences [ 31 ]. Common tools include FASTQ [ 33 ], NGSQC [ 34 ], RNA-SeQC [ 35 ], Trimmomatic [ 36 ], PRINSEQ [ 37 ] and Soapnuke [ 38 ].

The next step is to map the clean reads to either a genome or a transcriptome. There are some mapping tools available, including Tophat2 [ 39 ], HISAT2 [ 40 ], STAR [ 41 ], BWA [ 42 ] and Bowtie [ 43 ]. After alignment, another type of software, such as Cufflinks [ 44 ], StringTie [ 45 ], Trinity [ 46 ], SOAPdenovoTrans [ 47 ] and Trans-AByS [ 48 ] can be used to assemble transcripts from short-reads. When the transcript model is established, its expression can be quantified at the gene, transcript and exon levels. Commonly used software for gene-level quantification includes FeatureCount [ 49 ] and HTSeq-count [ 50 ]. Transcript level quantitative software includes Cufflinks [ 44 ], eXpress [ 51 ] and RSEM [ 52 ]. DEXSeq is a software for exon level quantification [ 53 ]. In addition, there are some alignment-free quantification tools such as Kallisto [ 54 ], Sailfish [ 55 ] and Salmon [ 56 ], which have the advantage of marked computational resource saving. After normalizing, an expression matrix is generated, and statistical methods can be used to identify differentially expressed genes. DESeq2 [ 57 ] and edgeR [ 58 ] are commonly used to perform this task.

Applications of RNA-sequencing in cancer research

Genomic data, such as RNA-seq, have become widely available due to the popularity of high-throughput sequencing technology [ 59 ]. As an important part of next-generation sequencing, RNA sequencing has made great contributions in various fields, especially cancer research, including studies on differential gene expression analysis and cancer biomarkers, cancer heterogeneity and evolution, cancer drug resistance, the cancer microenvironment and immunotherapy, neoantigens, etc. (Fig.  5 ).

figure 5

Applications of RNA-seq in differential expression analysis and cancer biomarkers, cancer heterogeneity and drug resistance, cancer immune microenvironment, immunotherapy and neoantigen. a Differential expression analysis by RNA sequencing can identify potential biomarkers, including fusion transcript, lncRNA, miRNA and circRNA. b The heterogeneity and drug resistance of cancer cells identified by RNA-seq. c Novel molecular signature, regulatory protein and unknown subtypes in cancer infiltrating immune cells and potential resistance effector in immunotherapy can be identified by RNA-seq; d Neoantigen profiling by RNA-seq and TCR modification targeted neoantigens

Differential gene expression analysis and cancer biomarkers

Differential gene expression analysis is one of the most common applications of RNA sequencing [ 60 ]. Samples from different backgrounds (different species, tissues and periods) can be used for RNA sequencing to identify differentially expressed genes, revealing their function and potential molecular mechanisms [ 61 ]. More importantly, differential gene expression analysis facilitates the discovery of potential cancer biomarkers [ 62 ]. Many studies have shown that gene fusions are closely related to oncogenesis and are appreciated as both ideal cancer biomarkers and therapeutic targets [ 63 ]. Gene fusions in clinical samples are primarily detected by RNA-CaptureSeq. Compared to whole transcriptome sequencing, RNA-CaptureSeq has significantly higher sequencing depth [ 27 , 64 , 65 ]. It has been reported that the NUP98-PHF23 fusion gene is likely to be a novel therapeutic target in acute myeloid leukemia (AML) [ 66 ]. Recently, a variety of recurrent gene fusions, including ESR1-CCDC170, SEC16A-NOTCH1, SEC22B-NOTCH2 and ESR1-YAP1, have been identified in breast cancer, indicating that recurrent gene fusion is one of the key drivers for cancer [ 67 ]. Several novel configurations of  BRAF, NTRK3 and RET gene fusions have been identified in colorectal cancer [ 68 ]. These fusions may promote the development of malignancy and provide new targets for personalized treatment [ 68 ]. In addition, some special genomic factors have been discovered as biomarkers by RNA sequencing, including miRNA, lncRNA and circRNA, which are widely present in various types of cancer [ 69 , 70 , 71 ]. A recent example is circRNA_0001178 and circRNA_0000826, which are biomarkers of colorectal cancer metastasis to the liver [ 72 ]. By applying both RNA sequencing and small RNA sequencing, a study on pancreatic cancer identified differential expression of simple repetitive sequences (SSRs) and demonstrated that the frequency of SSR motifs changed dramatically, which is expected to become a tumor biomarker [ 73 ]. In addition to nucleic acid biomarkers, RNA-seq combined with immunohistochemistry and western blot has also identified certain proteins as cancer biomarkers, such as nuclear COX2 (cyclooxygenase2) in combination with HER2 (human epidermal growth factor receptor type 2), which may serve as potential biomarkers for the diagnosis and prognosis of colorectal cancer [ 74 ]. Similar examples identified using RNA-seq profiling analysis include ISG15 (Interferon-stimulated gene 15) in nasopharyngeal carcinoma [ 75 ] and DMGDH (dimethylglycine dehydrogenase) in hepatocellular carcinoma [ 76 ]. Data-mining analysis of RNA sequencing data and other clinical data has identified that the isoforms of peroxiredoxins also can be expected the prognostic biomarkers for predicting overall survival and relapse-free survival in breast cancer [ 77 ]. Increasing differentially expressed genes are being identified by RNA sequencing, and new potential cancer biomarkers are being continuously discovered (Table 2 ). However, sufficient clinical practice is needed to confirm the diagnostic and predictive applications of these biomarkers in cancer.

RNA-seq could detect early mutations as well as high molecular risk mutations, thus can discover novel cancer biomarkers and potential therapeutic targets, monitoring of diseases and guiding targeted therapy during early treatment decisions. Tumor mutation burden (TMB) is considered as a potential biomarker for immune checkpoint therapy and prognosis [ 78 , 79 ]. RNA-seq can be used to explore the application value of TMB in diffuse glioma [ 78 ]. Through the RNA-seq, MET exon 14 mutation and isocitrate dehydrogenase 1 (IDH1) mutation were identified as new potential therapeutic targets in lung adenocarcinoma and chondrosarcoma patients, respectively [ 80 , 81 ]. Several studies have shown that RNA sequencing can effectively improve the detection rate on the basis of DNA sequencing, provide more comprehensive detection results and achieve a better curative effect for targeted therapy [ 82 ]. In addition, it has been proved that IDH mutation is a good prognostic marker for glioma by RNA-seq [ 83 ]. Targeted therapy is also considered to enhance or replace cytotoxic chemotherapy regimen in cancer including AML [ 84 , 85 , 86 ].

ScRNA-seq also has some new discoveries in diagnosis. For example, scRNA-seq data can be used to infer copy number variations (CNV) and to distinguish malignant from non-malignant cells. The infer CNV algorithm, which was used in the study of glioblastoma, uses averaging relative expression levels over large genomic regions to infer chromosome copy number variation [ 87 ]. Similar examples include head and neck cancer [ 88 ] and human oligodendroglioma [ 89 ]. It is reported that RNA sequence of tumor-educated blood platelets (TEPs) can also become a blood-based cancer diagnosis method [ 90 ]. It should be noted that the lack of detailed functional implications of the identified RNAs in platelets in the field of platelet RNA research is also an urgent problem to be solved [ 91 ].

Cancer heterogeneity and evolution

Heterogeneity has always existed during the transformation of normal cells to cancer cells. The continuous accumulation of heterogeneity may reflect the evolution of cancer [ 109 ]. Early RNA sequencing detected all RNA transcripts in a given tissue or cell group, ignoring differences in individual cells. Transcriptome profiling of single-cell RNA sequencing solves this problem by providing single-cell resolution of the transcriptome [ 3 ]. In melanoma, single-cell RNA-seq was used to analyze 4645 tumor cells from 19 patients, including cancer cells, immune cells, mesenchymal cells and endothelial cells. Transcriptomic data from different single cells revealed that heterogeneity of cells within the same cancer is associated with cell cycle, spatial background and drug resistance [ 110 ]. A recent single-cell RNA-seq study of 49 samples of metastatic lung cancer revealed changes in plasticity induced by non-small cell lung cancer treatment, providing new directions for clinical treatment [ 111 ]. Single-cell RNA sequencing also integrates a variety of information in a single cancer cell, deciphering the secrets of cancer heterogeneity and evolution [ 112 ]. Compared with scRNA-seq, another emerging technology spatial transcriptome sequencing incorporates information on the spatial location of cells. In prostate cancer, using spatial transcriptomics technology, the transcriptome of nearly 6750 tissue regions was analyzed, revealing the whole-tissue gene expression heterogeneity of the entire multifocal prostate cancer and accurately describing the range of cancer foci [ 113 ]. In a study of breast cancer tissues, the results of spatial transcriptome sequencing revealed that gene expression among different regions was surprisingly highly heterogeneous [ 22 ]. In recent years, single-nucleus RNA sequencing (snRNA-seq) has also received extensive attention due to its solving the problem that single-cell RNA sequencing cannot be applied to frozen specimens and cannot obtain all cell types in a given tissue [ 114 , 115 ]. The emerging technology of RNA sequencing will contribute to research on cancer heterogeneity and evolution.

Cancer drug resistance

Drug resistance is a main reason leading to cancer treatment failure. However, the molecular mechanisms underlying drug resistance are still poorly understood [ 116 ]. RNA sequencing became a vital tool for revealing the mechanisms of cancer drug resistance. In breast cancer, single-cell RNA sequencing identified a tumor-infiltrating immunosuppressive immature myeloid cell that leads to drug resistance [ 117 ]. Another study identified a new COX7B gene related to platinum resistance and a surrogate marker CD63 in cancer cells by single-cell RNA-seq [ 118 ]. RNA sequencing has also demonstrated that cancer cells that wake up from a dormant state produce large amounts of BORIS (brother of the regulator of imprinted sites), which can regulate the expression of survival genes in drug-resistant neuroblastoma cells [ 119 ]. Identifying special molecules that mediate these processes could help us understand the occurrence of drug resistance. Single-cell transcriptomics can be used to study different modes of chemoresistance in tumor cells and has shown that pre-existing drug-resistant cells can be selected through higher phenotypic intratumoral heterogeneity, while phenotypic homogeneous cells use other mechanisms to trans-differentiate under drug-selection [ 120 ]. In one study of pancreatic ductal adenocarcinoma, human pancreatic cancer (PANC-1) cells and gemcitabine-resistant PANC-1 cell lines were compared by RNA sequencing, and two circRNAs were identified as both novel biomarkers and potential therapeutic targets for gemcitabine resistant patients [ 121 ]. RNA-seq has also conducted in-depth research on the drug resistance of hematological malignancies. Through RNA-seq, it has been found that non-coding RNAs and fusion genes play an important role in mediating the drug resistance of hematological malignancies [ 122 ]. A good example is to compare the circRNA expression profile of the drug-resistant acute myeloid leukemia cell with its parent cell, and determine the circRNAs involved in drug resistance [ 123 ]. Similarly, the novel MEF2D-BCL9 fusion transcript identified by RNA-seq was found to increase HDAC9 (histone deacetylase 9) expression and to enhance the resistance to dexamethasone in acute lymphocytic leukemia (ALL) [ 124 ]. Leukemia stem cells (LSCs), a rare cell population assumed to be responsible for relapse, is crucial to improve the prognosis of patients [ 125 , 126 ]. RNA-seq analysis showed that LSCs have a unique lncRNA signature with functional relevance and therapeutic potential, providing an explanation for chemotherapy resistance and disease recurrence [ 127 ].

The cancer microenvironment and immunotherapy

The immune system plays a critical role in the cancer microenvironment, affecting several stages of cancer development, including tumorigenesis, progression and metastasis, through tumor-infiltrating lymphocytes (TILs) [ 128 ]. TILs and their interactions with malignant cells and stromal cells make up the cancer immune microenvironment. Due to the heterogeneity of cancer, it is difficult to define the exact pro- or anti-cancer function of certain immune cells. Cancer heterogeneity also causes the varied clinical efficacy observed in patients treated with immunotherapies due to different responses of different subclones [ 129 ]. Transcriptomic profiling by RNA-seq, in particular scRNA-seq, provides comprehensive information on cellular activity and interactions among cells in the tumor microenvironment (TME). ScRNA-seq enables genomic and molecular profiling of high quantity and quality individual immune cells and assessment of cellular heterogeneity to depict the immune system spectrum in the cancer microenvironment [ 130 , 131 , 132 ]. ScRNA-seq data demonstrated that compared to normal tissues, cancer tissues exhibited significantly higher heterogeneity in the immune microenvironment, and a continuity in T cell activation resulting from polyclonal T cells and heterogeneous antigen-presenting cells has been identified [ 133 ].

ScRNA-seq of tumor-infiltrating T cells in metastatic melanoma identified transcription factor NFATC1 (nuclear factor of activated T cells 1) as a potential molecular signature of T cell exhaustion programs and revealed the depletion of low-exhaustion T cells in expanded clones of T cells [ 110 ]. Combining scRNA-seq with assembled T cell receptor (TCR) sequences, 11 T cell subsets, such as CD8  +  T cells and CD8  +  FOXP3  +  regulatory-like cells, and their genomic signatures, were identified in hepatocellular carcinoma (HCC), providing valuable insights for understanding the immune landscape of infiltrating T cells in HCC [ 134 ]. Cancer infiltrating T cells also play an anti-tumor role through impairment of an autophagy protein, LC3 (microtubule-associated protein 1A/1B-light chain 3, often short for LC3)-associated phagocytosis (LAP), demonstrating the role of autophagy in oncogenesis and suppression revealed by scRNA-seq [ 135 ]. In addition to solid tumors, scRNA-seq of acute myeloid leukemia patients detected diverse immunomodulatory genes that suppress T cell function [ 136 ]. By CSOmap, a computational tool for scRNA-seq, the CCL4-CCR8 directed interaction between Tregs and Texs, as well as reduced proliferation of Texs, was characterized [ 137 ]. Notably, findings also revealed that tumor-infiltrating T cells exhibited more interactions among themselves than with T cells from peripheral blood and different interactions between tumors and T cells, indicating a varied response to immunotherapy and a potential trend for immune escape [ 137 ].

In the cancer immune microenvironment, neutrophils, in addition to T cells, are also key components of cancer progression and cancer drug resistance [ 138 , 139 , 140 , 141 ]. Through scRNA-seq of murine sarcomas and certain human cancers, neutrophils with CSF3R (colony stimulating factor 3 receptor) expression were found to be a part of type 1 antitumor immunity associated with unconventional CD4 − CD8 − αβ T cells (UTCαβ) in anti-cancer immunity, indicating better prognosis [ 142 ]. ScRNA-seq of metastatic breast cancer and CD45 cells from primary cancer identified neutrophils as pro- and anti-tumorigenic or metastatic, in which pro-tumorigenic and metastatic neutrophils are induced by IL11 expressing cancer subclones, resulting in polyclonal metastasis [ 143 ]. This observation also provides new insight into anti-cancer immunotherapy by targeting neutrophils [ 143 ]. With scRNA-seq of CD4 and CD8 T cells, several crucial pathways with anti-cancer function were revealed [ 144 ].

The balance between immune reaction and immune tolerance is the basis of immune homeostasis, which is also involved in anti-cancer immunity and oncogenesis. scRNA-seq of monocytes and dendritic cells (DCs) separated from a single lymph node melanoma metastasis revealed a conserved homeostatic module regulated by suppressor-of-cytokine-2 (SOCS2) protein and IFNγ [ 145 ]. SOCS2 serves an essential regulatory role in anti-tumor immunity and T cell priming through DCs. This highly conserved homeostatic program establishes a connection between autoimmune prevention and immune surveillance in cancer [ 145 ].

Immunotherapies, especially immune checkpoint blockade (ICB), has opened a new chapter for anti-cancer therapy with remarkable responses from targeting programmed death 1 (PD1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) [ 146 , 147 , 148 ]. However, only a few patients benefit from ICB, and severe side effects were observed [ 149 , 150 ]. Obviously, various unknown determinants are correlated with the outcome of immunotherapies in addition to well-known factors such as PD1/PD-L1/CTLA-4 expression and mismatch repair deficiency [ 151 , 152 , 153 , 154 , 155 ]. Therefore, it is paramount to identify potential effectors for ICB efficacy. By analyzing RNA-seq data from melanoma patients who underwent anti-PD1 and anti-CTLA4 treatment, a potential ICB resistance effector SERPINB9 (a member of the serine protease inhibitor (serpin) family) and the connection between cytotoxic T lymphocytes (CTL) infiltration level and ICB response were characterized [ 156 ]. A sub-population cells with immunotherapy persistence have been identified by scRNA-seq and were found to have stem cell-like states with the expression of stem cell antigen-1 (Sca-1) and Snai1 [ 157 ].

Another immunotherapy, myeloid-targeted immunotherapy, is based on the complexity of tumor-infiltrating myeloid cells, including DCs and tumor-associated macrophages (TAMs) revealed by scRNA-seq [ 158 ]. Through scRNA-seq of immune cells from colorectal cancer patients, C1QC  +  and SPP1  +  TAMs, two subsets of TAMs, were identified, and the mechanism of myeloid-targeted immunotherapy, such as anti-CSF1R (colony stimulating factor 1 receptor) and CD40 agonist, was revealed [ 159 ]. Intracellular staining and sequencing (INs-seq), a novel technology integrating scRNA-seq and intracellular protein activity measurements, revealed novel Arg1  +  Trem2  +  regulatory myeloid (Mreg) cells and demonstrated that depletion of Trem2 led to deduction of exhausted CD8 T cells with increased NK and cytotoxic T cells and cancer suppression by reducing accumulation of intratumoral Mreg cells [ 160 ].

Cancer neoantigens

Neoantigens, human leukocyte antigen (HLA)-bound peptides derived from cancer-specific somatic mutations or gene fusions during tumor growth, are another crucial regulator of the clinical response to immunotherapy [ 161 ]. Higher intratumor neoantigen heterogeneity and clonal neoantigen burden increases sensitivity to ICB and contributes to better clinical outcome in patients with melanoma and advanced non-small cell lung cancer [ 162 ]. This kind of antigen is an optimal target for anti-cancer immunotherapy, enhancing neoantigen-specific T cell activity, and a vaccine targeting personal neoantigens for melanoma patients has been developed [ 163 , 164 ]. Given all these promising features of personalized medicine targeting neoantigens in tumors, massive parallel profiling of tumor neoantigen burden is necessary for improving clinical efficacy and a deeper understanding of the neoantigen landscape. An RNA-seq-based transcriptomic approach is an efficient tool for neoantigen profiling in many studies. It was revealed that homology of neoantigen and somatic-mutation induced pathogens are important in response prediction in anti-CTLA4 treated melanoma [ 165 ]. In addition to melanoma, other studies found reduced neoantigen load in triple-negative and HER2 breast cancers [ 166 ], diverse neoantigen abundance in non-small-cell lung cancer patients with different treatment strategies [ 167 ], a decreased ratio of neoantigen expression to predicted neoantigens in recurrent glioma due to immune selection pressure [ 168 ], a negative correlation between neoantigen abundance and clinical outcome in selected solid tumors [ 169 ] and different neoantigen landscapes in immune filtration and T cell dysfunction based on histology in salivary gland carcinoma (SGC) patients [ 170 ].

A neoantigen prediction program, Neopepsee, based on RNA-seq data and somatic mutation, can be utilized to detect potential neoantigens for personal vaccine development with reduced false-positive rate compared to binding affinity prediction [ 171 ]. ScanNeo is another prediction computational pipeline based on RNA-seq that aims to identify insertion and deletion derived neoantigens, which was validated in prostate cancer [ 172 ], and ASNEO, which identifies personal-specific alternative splicing derived neoantigens [ 173 ]. Several neoantigens have been identified to be related to cancer prognosis and might be potential targets of immunotherapies, such as the TP53 neoantigen for HCC patients [ 174 ]. For the anti-neoantigen immunotherapy in cancer, a new strategy involving neoantigen-specific TCRs modification has been proposed, and scRNA-seq has been applied to isolate neoantigen-specific TCRs for further clinical application [ 175 ].

Conclusions and perspectives

High-throughput RNA-seq technology has been a major tool to explore the transcriptome. The rapid development of RNA-seq technology not only saves time and cost but also sheds light on many new research fields. However, there are still limitations of RNA-seq technology that need to be improved.

For short-read length RNA-seq technologies, bias and imperfections are primarily generated in sequencing library preparation and short read assembly. It is difficult for these methods to correctly identify multiple isoforms from a certain gene. To overcome the disadvantage of short read length, improved read coverage and sequencing depth is required. Long-read length RNA-seq technologies avoid shortcomings in template amplification, reduce the false positive rate in splice junction detection and enable the identification of unannotated longer transcripts, overcoming the common limitations of short-read sequencing [ 176 , 177 ]. However, this method suffers from the drawback of reduced throughput, higher cost and higher sequencing error rate, especially insertion-deletion errors. To reduce random errors, PacBio circular consensus-sequencing (CCS) was developed to increase sequencing depth by rereading molecules several times. However, it also reduces the identification rate of unique isoforms. In addition, the sensitivity of long-read sequencing for identification of differentially expressed genes is lower compared to short-read sequencing [ 178 , 179 , 180 ]. Thus, hybridization of long-read and short-read sequencing has been reported to yield a more comprehensive and accurate analysis [ 181 ].

Improvements in the throughput of RNA sequencing technology have resulted in billions of sequencing reads, bringing great challenges to the computational process, such as data storage, transmission, quality control and data analysis, including read mapping, transcript assembly and read normalization. Therefore, it is important for bioinformatics to keep pace with the continuous developments of RNA-seq technologies. Notably, bias could be produced due to differences in read data handling, necessitating the improvement of current bioinformatics pipelines.

RNA-seq measures gene expression by the read counts, which always containing missing values, thus results in information loss of specific gene and negative impact on downstream analysis. To overcome this problem, missing data need to be imputed and analyzed by several methods, such as optimal clustering with missing values [ 182 ]. For scRNA-seq, the proportion of genes with zero or low expression varies across cells due to biological or technical bias. For example, batch effects can come from cells captured and sequenced in different conditions [ 183 ]. Imputation methods, such as SAVER, MAGIC and kNN-smoothing, are recommended for scRNA-seq [ 184 ]. Another method named batch effects correction with unknown subtypes for scRNA-seq data (BUSseq) utilizes Bayesian hierarchical model and can also be used to correct batch effects and missing data [ 185 ].

Combination of data from multi-omics sequencing can undoubtedly expand the application of RNA-seq. For example, Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) was developed by utilizing hyperactive Tn5 transposase to identify open chromatin region and transcriptional factor (TF) binding sites [ 186 ]. The integration of ATAC-seq and RNA-seq enables the reveal of TF-targeted genes and their transcripts [ 187 , 188 ]. Chromatin conformation capture analysis (3C) technology and its several derivatives including circular chromosome conformation capture (4C), carbon copy chromosome conformation capture (5C), ChIP-Loop, Hi-C and capture Hi-C were developed and improved to detect chromatin structure as well as unknown interacting regions [ 189 , 190 , 191 ]. It has been reported that combined analysis of RNA-seq and chromatin structure can detect structure variation-related differentially expressed genes [ 192 , 193 , 194 ].

Epitranscriptomics is a crucial part of gene expression, and methylation of adenosine at the N6 position (m6A) is the most abundant [ 195 ]. Traditional RNA-seq needs reverse transcription before sequencing and thus easily loses the information of transcriptome complexity. This shortcoming can be overcome by directly sequencing native RNA molecules using methods such as nanopore sequencing. Transcript modifications could be inferred from the current signal as the modified RNA molecules passing nanopore cause a characteristic temporary current blockade, which enables the detection of diverse modifications such as m6A or 5-methylcytosine (m5C) [ 196 , 197 , 198 ].

ScRNA-seq is a powerful technology to facilitate further exploration in cancer research and also has been employed in the detection of cancer stem cell subpopulation, metabolic switch in cancer-draining lymph nodes and therapy-induced adaption of cancer cells [ 111 , 199 , 200 ]. Combined with cell sorting or ligand-receptor interaction, scRNA-seq was utilized in cellular interaction, cell spatial organization as well as molecular crosstalk characterization [ 137 , 201 , 202 ]. Coupling of parallel CRISPR (clustered regularly interspaced short palindromic repeats)-pooled screen, scRNA-seq enables the simultaneous analysis of genomic perturbation and transcriptional activity to detect heterogeneous cell type as well as crucial factors of complexity regulatory mechanism [ 203 , 204 , 205 ]. ScNT-seq, single-cell metabolically labeled new RNA tagging sequencing, brings RNA-seq into time resolution by identifying RNAs transcribed at different stage [ 206 ]. Utilizing SNP-based demultiplexing of scRNA-seq data, MIX-Seq was developed to study cancer cell reaction to pharmacologic treatment [ 207 ]. Another technology, snRNA-seq, is invaluable for detecting cellular heterogeneity of cancer and has been employed to identification of a sub-population of adipocytes regulating cancer genesis [ 208 ].

Taken together, RNA-seq has been applied in an impressively wide range of cancer research. All applications in cancer research rely on the boost of advanced RNA-seq technologies, especially the combination of scRNA-seq and spatial transcriptomics as well as data from multi-omics, which will bring RNA-seq technologies into single-cell resolution and tissue-level transcriptomics, providing new insight into cancer diagnosis, treatment and prevention.

Availability of data and materials

Not applicable.

Abbreviations

  • RNA sequencing

Single-cell RNA sequencing

Sequencing by Oligonucleotide Ligation and Detection

DNA nanoball sequencing

Next-generation sequencing

Pacific Biosciences single-molecule real-time

Oxford Nanopore Technologies

Single-cell combinatorial indexing RNA sequencing

Split-pool ligation-based transcriptome sequencing

Laser capture microdissection

Fluorescent in situ RNA sequencing

Rolling-circle amplification

Acute myeloid leukemia

Simple repetitive sequences

Cyclooxygenase2

Human epidermal growth factor receptor type 2

Interferon-stimulated gene 15

Dimethylglycine dehydrogenase

Tumor mutation burden

Isocitrate dehydrogenase

Copy number variations

Tumor-educated blood platelets

Single-nucleus RNA-sequencing

Brother of the regulator of imprinted sites

Acute lymphocytic leukemia

Leukemia stem cells

Tumor-infiltrating lymphocytes

Tumor microenvironment

Nuclear factor of activated T cells 1

T cell receptor

Hepatocellular carcinoma

Microtubule-associated protein 1A/1B-light chain 3-associated phagocytosis

Colony stimulating factor 3 receptor

Unconventional CD4 − CD8 −  αβ T cells

Dendritic cells

Suppressor-of-cytokine-2 protein

Immune checkpoint blockade

Targeting programmed death 1

Programmed death-ligand 1

Cytotoxic T-lymphocyte-associated protein 4

Cytotoxic T lymphocytes

Stem cell antigen-1

Tumor-associated macrophages

Colony stimulating factor 1 receptor

Intracellular staining and sequencing

Regulatory myeloid cells

Human leukocyte antigen

Salivary gland carcinoma

Circular consensus-sequencing

Assay for Transposase-Accessible Chromatin using sequencing

Transcriptional factor

Chromatin conformation capture analysis

Circular chromosome conformation capture

Carbon copy chromosome conformation capture

N6 position

5-Methylcytosine

Clustered regularly interspaced short palindromic repeats

Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437:376–80.

Article   CAS   PubMed   PubMed Central   Google Scholar  

Cieślik M, Chinnaiyan AM. Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet. 2018;19:93–109.

Article   PubMed   CAS   Google Scholar  

Suvà ML, Tirosh I. Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell. 2019;75:7–12.

Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953;171:737–8.

Article   CAS   PubMed   Google Scholar  

Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463–7.

Maxam AM, Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci USA. 1977;74:560–4.

Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature. 1977;265:687–95.

Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene. 2003;22:6497–507.

Li S, Tighe S, Nicolet C, Grove D, Levy S, Farmerie W, et al. Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study. Nat Biotechnol. 2014;32:915–25.

Article   PubMed   PubMed Central   CAS   Google Scholar  

A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014;32:903–14.

Mardis E. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9:387–402.

Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45.

Mardis E. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:287–303.

Article   CAS   Google Scholar  

Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18:1509–17.

Schadt EE, Turner S, Kasarskis A. A window into third-generation sequencing. Hum Mol Genet. 2010;19:R227–40.

Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323:133–8.

Hart C, Lipson D, Ozsolak F, Raz T, Steinmann K, Thompson J, et al. Single-molecule sequencing: sequence methods to enable accurate quantitation. Methods Enzymol. 2010;472:407–30.

Bayley H. Nanopore sequencing: from imagination to reality. Clin Chem. 2015;61:25–31.

Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6:377–82.

Cao J, Packer J, Ramani V, Cusanovich D, Huynh C, Daza R, et al. Comprehensive single-cell transcriptional profiling of a multicellular organism. Science. 2017;357:661–7.

Rosenberg A, Roco C, Muscat R, Kuchina A, Sample P, Yao Z, et al. Single-cell profiling of the developing mouse brain and spinal cord with split-pool barcoding. Science. 2018;360:176–82.

Ståhl P, Salmén F, Vickovic S, Lundmark A, Navarro J, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78–82.

Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363:1463–7.

Chen J, Suo S, Tam PP, Han JJ, Peng G, Jing N. Spatial transcriptomic analysis of cryosectioned tissue samples with geo-seq. Nat Protoc. 2017;12:566–80.

Ke R, Mignardi M, Pacureanu A, Svedlund J, Botling J, Wählby C, et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods. 2013;10:857–60.

Lee JH, Daugharthy ER, Scheiman J, Kalhor R, Yang JL, Ferrante TC, et al. Highly multiplexed subcellular RNA sequencing in situ. Science. 2014;343:1360–3.

Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA, et al. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol. 2011;30:99–104.

Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, et al. Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun. 2019;10:1388.

Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol. 2019;12:131.

Article   PubMed   PubMed Central   Google Scholar  

Chatterjee A, Ahn A, Rodger EJ, Stockwell PA, Eccles MR. A guide for designing and analyzing RNA-seq data. Methods Mol Biol. 2018;1783:35–80.

Article   PubMed   Google Scholar  

Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17:13.

Cock PJ, Fields CJ, Goto N, Heuer ML, Rice PM. The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Res. 2010;38:1767–71.

Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884–90.

Patel RK, Jain M. NGS QC Toolkit: a toolkit for quality control of next generation sequencing data. PLoS ONE. 2012;7:e30619.

DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics. 2012;28:1530–2.

Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.

Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27:863–4.

Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. SOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data. Gigascience. 2018;7:1–6.

PubMed   PubMed Central   Google Scholar  

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.

Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60.

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.

Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.

Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.

Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–5.

Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290–5.

Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, et al. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat Biotechnol. 2011;29:644–52.

Hurgobin B. Short read alignment using SOAP2. Methods Mol Biol. 2016;1374:241–52.

Robertson G, Schein J, Chiu R, Corbett R, Field M, Jackman SD, et al. De novo assembly and analysis of RNA-seq data. Nat Methods. 2010;7:909–12.

Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.

Anders S, Pyl PT, Huber W. HTSeq: a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–9.

Roberts A, Pachter L. Streaming fragment assignment for real-time analysis of sequencing experiments. Nat Methods. 2013;10:71–3.

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323.

Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data. Genome Res. 2012;22:2008–17.

Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525–7.

Patro R, Mount SM, Kingsford C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat Biotechnol. 2014;32:462–4.

Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417–9.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.

Moon M, Nakai K. Stable feature selection based on the ensemble L (1)-norm support vector machine for biomarker discovery. BMC Genomics. 2016;17:1026.

Zubovic L, Piazza S, Tebaldi T, Cozzuto L, Palazzo G, Sidarovich V, et al. The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. J Hematol Oncol. 2020;13:135.

Oshlack A, Robinson MD, Young MD. From RNA-seq reads to differential expression results. Genome Biol. 2010;11:220.

Govindarajan M, Wohlmuth C, Waas M, Bernardini MQ, Kislinger T. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol. 2020;13:134.

Wu H, Li X, Li H. Gene fusions and chimeric RNAs, and their implications in cancer. Genes Dis. 2019;6:385–90.

Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, et al. Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors. J Mol Diagn. 2017;19:682–96.

Mercer TR, Clark MB, Crawford J, Brunck ME, Gerhardt DJ, Taft RJ, et al. Targeted sequencing for gene discovery and quantification using RNA CaptureSeq. Nat Protoc. 2014;9:989–1009.

Togni M, Masetti R, Pigazzi M, Astolfi A, Zama D, Indio V, et al. Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. J Hematol Oncol. 2015;8:69.

Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat. 2016;158:219–32.

Kloosterman WP, Coebergh van den Braak RRJ, Pieterse M, van Roosmalen MJ, Sieuwerts AM, Stangl C, et al. A systematic analysis of oncogenic gene fusions in primary colon cancer. Cancer Res. 2017;77:3814–22.

Sun YM, Chen YQ. Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application. J Hematol Oncol. 2020;13:109.

Zhou X, Zhan L, Huang K, Wang X. The functions and clinical significance of circRNAs in hematological malignancies. J Hematol Oncol. 2020;13:138.

Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019;12:51.

Xu H, Wang C, Song H, Xu Y, Ji G. RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers. Mol Cancer. 2019;18:8.

Alisoltani A, Fallahi H, Shiran B, Alisoltani A, Ebrahimie E. RNA-seq SSRs and small RNA-seq SSRs: new approaches in cancer biomarker discovery. Gene. 2015;560:34–43.

Zhou FF, Huang R, Jiang J, Zeng XH, Zou SQ. Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer. Saudi J Gastroenterol. 2018;24:301–6.

Chen RH, Du Y, Han P, Wang HB, Liang FY, Feng GK, et al. ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma. Oncotarget. 2016;7:16910–22.

Liu G, Hou G, Li L, Li Y, Zhou W, Liu L. Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo. Oncotarget. 2016;7:32607–16.

Mei J, Hao L, Liu X, Sun G, Xu R, Wang H, et al. Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer. Biomark Res. 2019;7:16.

Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 2020;20:213.

Jiang T, Shi J, Dong Z, Hou L, Zhao C, Li X, et al. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. J Hematol Oncol. 2019;12:75.

Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109–19.

Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019;38:6835–49.

Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, et al. DNA-based versus RNA-based detection of MET Exon 14 skipping events in lung cancer. J Thorac Oncol. 2019;14:737–41.

Unruh D, Zewde M, Buss A, Drumm MR, Tran AN, Scholtens DM, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Sci Rep. 2019;9:8946.

Yu J, Jiang PYZ, Sun H, Zhang X, Jiang Z, Li Y, et al. Advances in targeted therapy for acute myeloid leukemia. Biomark Res. 2020;8:17.

Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11:3.

Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018;6:32.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401.

Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171(1611–24):e24.

Google Scholar  

Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539:309–13.

Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28:666–76.

Best MG, Vancura A, Wurdinger T. Platelet RNA as a circulating biomarker trove for cancer diagnostics. J Thromb Haemost. 2017;15:1295–306.

Zhu L, Li J, Gong Y, Wu Q, Tan S, Sun D, et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol Cancer. 2019;18:74.

Nie Y, Jiao Y, Li Y, Li W. Investigation of the clinical significance and prognostic value of the lncRNA ACVR2B-As1 in liver cancer. Biomed Res Int. 2019;2019:4602371.

Gong W, Yang L, Wang Y, Xian J, Qiu F, Liu L, et al. Analysis of survival-related lncRNA landscape identifies a role for LINC01537 in energy metabolism and lung cancer progression. Int J Mol Sci. 2019;20.

Hang D, Zhou J, Qin N, Zhou W, Ma H, Jin G, et al. A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer. Cancer Med. 2018;7:2783–91.

Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 2019;12:91.

Wang Z, Qin B. Prognostic and clinicopathological significance of long noncoding RNA CTD-2510F5.4 in gastric cancer. Gastric Cancer. 2019;22:692–704.

Luo T, Zhao J, Lu Z, Bi J, Pang T, Cui H, et al. Characterization of long non-coding RNAs and MEF2C-AS1 identified as a novel biomarker in diffuse gastric cancer. Transl Oncol. 2018;11:1080–9.

Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, et al. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019;79:1362–77.

CAS   PubMed   Google Scholar  

Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11:2156.

Yamada A, Yu P, Lin W, Okugawa Y, Boland CR, Goel A. A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Sci Rep. 2018;8:575.

Bo H, Fan L, Li J, Liu Z, Zhang S, Shi L, et al. High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis. J Cancer. 2018;9:4677–83.

Chen Q, Hu L, Chen K. Construction of a nomogram based on a hypoxia-related lncRNA signature to improve the prediction of gastric cancer prognosis. Front Genet. 2020;11:570325.

Guo YZ, Sun HH, Wang XT, Wang MT. Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma. J Zhejiang Univ Sci B. 2018;19:674–88.

Yao Y, Chen X, Lu S, Zhou C, Xu G, Yan Z, et al. Circulating long noncoding RNAs as biomarkers for predicting head and neck squamous cell carcinoma. Cell Physiol Biochem. 2018;50:1429–40.

Gong X, Siprashvili Z, Eminaga O, Shen Z, Sato Y, Kume H, et al. Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. Oncotarget. 2017;8:18657–69.

James AR, Schroeder MP, Neumann M, Bastian L, Eckert C, Gökbuget N, et al. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. J Hematol Oncol. 2019;12:8.

Li S, Ma Y, Tan Y, Ma X, Zhao M, Chen B, et al. Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment. Cell Death Dis. 2018;9:651.

Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.

Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189–96.

Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. 2020;182(1232–51):e22.

Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2020.

Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstråhle J, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun. 2018;9:2419.

Bakken TE, Hodge RD, Miller JA, Yao Z, Nguyen TN, Aevermann B, et al. Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. PLoS ONE. 2018;13:e0209648.

Selewa A, Dohn R, Eckart H, Lozano S, Xie B, Gauchat E, et al. Systematic comparison of high-throughput single-cell and single-nucleus transcriptomes during cardiomyocyte differentiation. Sci Rep. 2020;10:1535.

Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12:134.

Wang Q, Guldner IH, Golomb SM, Sun L, Harris JA, Lu X, et al. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. Nat Commun. 2019;10:3817.

Tanaka N, Katayama S, Reddy A, Nishimura K, Niwa N, Hongo H, et al. Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63. Cancer Med. 2018;7:6193–204.

Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, et al. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019;572:676–80.

Sharma A, Cao EY, Kumar V, Zhang X, Leong HS, Wong AML, et al. Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. Nat Commun. 2018;9:4931.

Shao F, Huang M, Meng F, Huang Q. Circular RNA SIgnature predicts gemcitabine resistance of pancreatic ductal adenocarcinoma. Front Pharmacol. 2018;9:584.

Wang WT, Han C, Sun YM, Chen TQ, Chen YQ. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12:55.

Shang J, Chen WM, Liu S, Wang ZH, Wei TN, Chen ZZ, et al. CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res. 2019;85:106198.

Suzuki K, Okuno Y, Kawashima N, Muramatsu H, Okuno T, Wang X, et al. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol. 2016;34:3451–9.

Pallarès V, Unzueta U, Falgàs A, Sánchez-García L, Serna N, Gallardo A, et al. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. J Hematol Oncol. 2020;13:36.

Ding Y, Gao H, Zhang Y, Li Y, Vasdev N, Gao Y, et al. Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. J Hematol Oncol. 2016;9:93.

Bill M, Papaioannou D, Karunasiri M, Kohlschmidt J, Pepe F, Walker CJ, et al. Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia. 2019;33:2169–82.

Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. Cell. 2016;164:1198–211.

Burrell RA, Swanton C. Re-evaluating clonal dominance in cancer evolution. Trends Cancer. 2016;2:263–76.

Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013;498:236–40.

Pan Y, Lu F, Fei Q, Yu X, Xiong P, Yu X, et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J Hematol Oncol. 2019;12:124.

Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202–14.

Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293–308.

Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342–56.

Cunha LD, Yang M, Carter R, Guy C, Harris L, Crawford JC, et al. LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance. Cell. 2018;175:429–41.

van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265–81.

Ren X, Zhong G, Zhang Q, Zhang L, Sun Y, Zhang Z. Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly. Cell Res. 2020;30:763–78.

Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528:413–7.

Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16:431–46.

Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao AS, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30:120–35.

Massara M, Bonavita O, Savino B, Caronni N, Mollica Poeta V, Sironi M, et al. ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity. Nat Commun. 2018;9:676.

Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178(346–60):e24.

Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019;21:879–88.

Rath J, Bajwa G, Carreres B, Hoyer E, Gruber I, Martínez-Paniagua M, et al. Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4 T cells. Sci Adv. 2020;6:eaaz7809.

Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, et al. IFNγ-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell. 2017;170(127–41):e15.

Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, et al. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019;12:42.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12:126.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.

Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–84.

Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.

Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018;11:142.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–8.

Sehgal K, Portell A, Ivanova E, Lizotte P, Mahadevan N, Greene J, et al. Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2020. https://doi.org/10.1172/JCI135038 .

Article   Google Scholar  

Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50:1317–34.

Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442–59.

Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182:872–85.

Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12:93.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–9.

Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1:11–5.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–21.

Nathanson T, Ahuja A, Rubinsteyn A, Aksoy BA, Hellmann MD, Miao D, et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol Res. 2017;5:84–91.

Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is associated with genomic aberrations in breast cancer. Cancer Res. 2017;77:3317–24.

Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, et al. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. Cancer Sci. 2017;108:170–7.

Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, et al. Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma. Cancer Immunol Res. 2019;7:1148–61.

Lv JW, Zheng ZQ, Wang ZX, Zhou GQ, Chen L, Mao YP, et al. Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types. J Pineal Res. 2019;66:e12557.

Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG, et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res. 2020;26:2859–70.

Kim S, Kim HS, Kim E, Lee MG, Shin EC, Paik S, et al. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. Ann Oncol. 2018;29:1030–6.

Wang TY, Wang L, Alam SK, Hoeppner LH, Yang R. ScanNeo: identifying indel-derived neoantigens using RNA-Seq data. Bioinformatics. 2019;35:4159–61.

Zhang Z, Zhou C, Tang L, Gong Y, Wei Z, Zhang G, et al. ASNEO: Identification of personalized alternative splicing based neoantigens with RNA-seq. Aging (Albany NY). 2020;12:14633–48.

Yang H, Sun L, Guan A, Yin H, Liu M, Mao X, et al. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. Cancer Immunol Immunother. 2020. https://doi.org/10.1007/s00262-020-02711-8 .

Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, et al. An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. Mol Ther. 2018;26:379–89.

Engström P, Steijger T, Sipos B, Grant G, Kahles A, Rätsch G, et al. Systematic evaluation of spliced alignment programs for RNA-seq data. Nat Methods. 2013;10:1185–91.

Sharon D, Tilgner H, Grubert F, Snyder M. A single-molecule long-read survey of the human transcriptome. Nat Biotechnol. 2013;31:1009–14.

Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012;13:341.

Tilgner H, Grubert F, Sharon D, Snyder MP. Defining a personal, allele-specific, and single-molecule long-read transcriptome. Proc Natl Acad Sci USA. 2014;111:9869–74.

Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20:631–56.

Antipov D, Korobeynikov A, McLean J, Pevzner P. hybridSPAdes: an algorithm for hybrid assembly of short and long reads. Bioinformatics. 2016;32:1009–15.

Boluki S, Zamani Dadaneh S, Qian X, Dougherty E. Optimal clustering with missing values. BMC Bioinform. 2019;20:321.

Hicks S, Townes F, Teng M, Irizarry R. Missing data and technical variability in single-cell RNA-sequencing experiments. Biostatistics. 2018;19:562–78.

Hou W, Ji Z, Ji H, Hicks S. A systematic evaluation of single-cell RNA-sequencing imputation methods. Genome biol. 2020;21:218.

Song F, Chan G, Wei Y. Flexible experimental designs for valid single-cell RNA-sequencing experiments allowing batch effects correction. Nat Commun. 2020;11:3274.

Buenrostro J, Giresi P, Zaba L, Chang H, Greenleaf W. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213–8.

Yang C, Ma L, Xiao D, Ying Z, Jiang X, Lin Y. Sparassis latifolia Integration of ATAC-Seq and RNA-Seq Identifies Key Genes in Light-Induced Primordia Formation of. Int J Mol Sci. 2019;21.

Wu X, Yang Y, Zhong C, Guo Y, Wei T, Li S, et al. Epinephelus coioides Integration of ATAC-seq and RNA-seq Unravels Chromatin Accessibility during Sex Reversal in Orange-Spotted Grouper ( Epinephelus coioides ). Int J Mol Sci. 2020;21.

Simonis M, Kooren J, de Laat W. An evaluation of 3C-based methods to capture DNA interactions. Nat Methods. 2007;4:895–901.

Lieberman-Aiden E, van Berkum N, Williams L, Imakaev M, Ragoczy T, Telling A, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326:289–93.

Mifsud B, Tavares-Cadete F, Young A, Sugar R, Schoenfelder S, Ferreira L, et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat Genet. 2015;47:598–606.

Crane E, Bian Q, McCord R, Lajoie B, Wheeler B, Ralston E, et al. Condensin-driven remodelling of X chromosome topology during dosage compensation. Nature. 2015;523:240–4.

Chen H, Seaman L, Liu S, Ried T, Rajapakse I. Chromosome conformation and gene expression patterns differ profoundly in human fibroblasts grown in spheroids versus monolayers. Nucleus. 2017;8:383–91.

Vara C, Paytuví-Gallart A, Cuartero Y, Le Dily F, Garcia F, Salvà-Castro J, et al. Three-dimensional genomic structure and cohesin occupancy correlate with transcriptional activity during spermatogenesis. Cell Rep. 2019;28(352–67):e9.

Zeng C, Huang W, Li Y, Weng H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13:117.

Jenjaroenpun P, Wongsurawat T, Wadley T, Wassenaar T, Liu J, Dai Q, et al. Decoding the epitranscriptional landscape from native RNA sequences. Nucleic Acids Res. 2020. https://doi.org/10.1093/nar/gkaa620 .

Article   PubMed Central   Google Scholar  

Parker M, Knop K, Sherwood A, Schurch N, Mackinnon K, Gould P, et al. Nanopore direct RNA sequencing maps the complexity of Arabidopsis mRNA processing and mA modification. eLife. 2020;9.

Zhang S, Li R, Zhang L, Chen S, Xie M, Yang L, et al. New insights into Arabidopsis transcriptome complexity revealed by direct sequencing of native RNAs. Nucleic Acids Res. 2020;48:7700–11.

Pan X, Zhang H, Xu D, Chen J, Chen W, Gan S, et al. Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis. Int J Biol Sci. 2020;16:3149–62.

Li Y, Chen C, Chen J, Lai Y, Wang S, Jiang S, et al. Single-cell analysis reveals immune modulation and metabolic switch in tumor-draining lymph nodes. Oncoimmunology. 2020;9:1830513.

Giladi A, Cohen M, Medaglia C, Baran Y, Li B, Zada M, et al. Dissecting cellular crosstalk by sequencing physically interacting cells. Nat Biotechnol. 2020;38:629–37.

Caruso F, Garofano L, D'Angelo F, Yu K, Tang F, Yuan J, et al. A map of tumor-host interactions in glioma at single-cell resolution. GigaScience. 2020;9.

Jaitin D, Weiner A, Yofe I, Lara-Astiaso D, Keren-Shaul H, David E, et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-seq. Cell. 2016;167:1883–96.

Datlinger P, Rendeiro A, Schmidl C, Krausgruber T, Traxler P, Klughammer J, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017;14:297–301.

Genga R, Kernfeld E, Parsi K, Parsons T, Ziller M, Maehr R. Single-cell RNA-sequencing-based CRISPRi screening resolves molecular drivers of early human endoderm development. Cell Rep. 2019;27:708–18.

Qiu Q, Hu P, Qiu X, Govek K, Cámara P, Wu H. Massively parallel and time-resolved RNA sequencing in single cells with scNT-seq. Nat Methods. 2020;17:991–1001.

McFarland J, Paolella B, Warren A, Geiger-Schuller K, Shibue T, Rothberg M, et al. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat commun. 2020;11:4296.

Sun W, Dong H, Balaz M, Slyper M, Drokhlyansky E, Colleluori G, et al. snRNA-seq reveals a subpopulation of adipocytes that regulates thermogenesis. Nature. 2020;587:98–102.

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81300398 and 81974436); Key-Area Research and Development Program of Guangdong Province (2020B1111030005); The Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2019ZT08Y485); Key Program of Marine Economy Development (Six Marine Industries) Special Foundation of Department of Natural Resources of Guangdong Province (GDNRC [2020]070); The Fundamental Research Funds for the Central Universities (19ykzd06) and the Opening Fund of Guangdong Key Laboratory of Marine Materia Medica (LMM2020-4).

Author information

Mingye Hong and Shuang Tao have contributed equally to this work

Authors and Affiliations

Institute of Laboratory Medicine, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan, 523808, China

Mingye Hong, Xuanmei Huang, Shaohui Huang & Hua Zhang

Biotherapy Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China

Shuang Tao, Li-Ting Diao, Shu-Juan Xie & Zhen-Dong Xiao

Health Science Center, The University of Texas, Houston, 77030, USA

You can also search for this author in PubMed   Google Scholar

Contributions

M.H. and S.T. wrote and edited this manuscript and created figures and tables. L.Z., L-T. D., X-M. H., S-H. H., S-J. X., Z-D. X and H.Z. reviewed and revised the manuscript. Z-D. X and H.Z. provided direction and guidance throughout the preparation of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Zhen-Dong Xiao or Hua Zhang .

Ethics declarations

Ethics approval and consent to participate, consent for publication, competing interests.

The authors declare that they have no competing interests.

Additional information

Publisher's note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Hong, M., Tao, S., Zhang, L. et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol 13 , 166 (2020). https://doi.org/10.1186/s13045-020-01005-x

Download citation

Received : 31 October 2020

Accepted : 22 November 2020

Published : 04 December 2020

DOI : https://doi.org/10.1186/s13045-020-01005-x

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

  • Application

Journal of Hematology & Oncology

ISSN: 1756-8722

cancer and its types research paper

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • View all journals
  • Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • Review Article
  • Published: 10 September 2021

Stress and cancer: mechanisms, significance and future directions

  • Anabel Eckerling   ORCID: orcid.org/0000-0002-6530-9346 1 ,
  • Itay Ricon-Becker   ORCID: orcid.org/0000-0001-8440-1634 1 ,
  • Liat Sorski   ORCID: orcid.org/0000-0002-2087-1984 1 ,
  • Elad Sandbank   ORCID: orcid.org/0000-0003-3374-5052 1 &
  • Shamgar Ben-Eliyahu   ORCID: orcid.org/0000-0003-3832-0678 1  

Nature Reviews Cancer volume  21 ,  pages 767–785 ( 2021 ) Cite this article

12k Accesses

89 Citations

221 Altmetric

Metrics details

  • Cancer epidemiology
  • Cancer therapy

The notion that stress and cancer are interlinked has dominated lay discourse for decades. More recent animal studies indicate that stress can substantially facilitate cancer progression through modulating most hallmarks of cancer, and molecular and systemic mechanisms mediating these effects have been elucidated. However, available clinical evidence for such deleterious effects is inconsistent, as epidemiological and stress-reducing clinical interventions have yielded mixed effects on cancer mortality. In this Review, we describe and discuss specific mediating mechanisms identified by preclinical research, and parallel clinical findings. We explain the discrepancy between preclinical and clinical outcomes, through pointing to experimental strengths leveraged by animal studies and through discussing methodological and conceptual obstacles that prevent clinical studies from reflecting the impacts of stress. We suggest approaches to circumvent such obstacles, based on targeting critical phases of cancer progression that are more likely to be stress-sensitive; pharmacologically limiting adrenergic–inflammatory responses triggered by medical procedures; and focusing on more vulnerable populations, employing personalized pharmacological and psychosocial approaches. Recent clinical trials support our hypothesis that psychological and/or pharmacological inhibition of excess adrenergic and/or inflammatory stress signalling, especially alongside cancer treatments, could save lives.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

cancer and its types research paper

LeShan, L. Psychological states as factors in the development of malignant disease: a critical review. J. Natl Cancer Inst. 22 , 1–18 (1959).

CAS   PubMed   Google Scholar  

Mravec, B., Tibensky, M. & Horvathova, L. Stress and cancer. Part I: mechanisms mediating the effect of stressors on cancer. J. Neuroimmunol. 346 , 577311 (2020). This review describes mechanisms by which stress affects specific hallmarks of cancer, emphasizing how stress is an integral part of cancer biology .

Article   CAS   PubMed   Google Scholar  

Cole, S. W. & Sood, A. K. Molecular pathways: β-adrenergic signaling in cancer. Clin. Cancer Res. 18 , 1201–1206 (2012).

Eng, J. W.-L. et al. A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol. Immunother. 63 , 1115–1128 (2014).

Article   CAS   PubMed   PubMed Central   Google Scholar  

Armaiz-Pena, G. N., Cole, S. W., Lutgendorf, S. K. & Sood, A. K. Neuroendocrine influences on cancer progression. Brain Behav. Immun. 30 , S19–S25 (2013).

Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A. & Sood, A. K. Sympathetic nervous system regulation of the tumour microenvironment. Nat. Rev. Cancer 15 , 563 (2015). This review describes the contribution of adrenergic signalling to cancer progression, focusing on the tumour microenvironment .

Armaiz-Pena, G. N., Colon-Echevarria, C. B. & Lamboy-Caraballo, R. Neuroendocrine regulation of tumor-associated immune cells. Front. Oncol. 9 , 1077 (2019). This review examines the effects of sympathetic and/or glucocorticoid signalling on various tumour-associated immune cells .

Article   PubMed   PubMed Central   Google Scholar  

Antoni, M. H. & Dhabhar, F. S. The impact of psychosocial stress and stress management on immune responses in patients with cancer. Cancer 125 , 1417–1431 (2019). This review discusses both preclinical and clinical studies and summarizes the effects of stress and stress management on immune indices in cancer, suggesting potential optimal strategies for stress management in patients with cancer .

Article   PubMed   Google Scholar  

Neeman, E. & Ben-Eliyahu, S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav. Immun. 30 , S32–S40 (2013).

Cui, B. et al. Cancer and stress: NextGen strategies. Brain Behav. Immun. 93 , 368–383 (2020).

Article   PubMed   CAS   Google Scholar  

Lutgendorf, S. K. & Andersen, B. L. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. Am. Psychol. 70 , 186–197 (2015).

Mravec, B., Tibensky, M. & Horvathova, L. Stress and cancer. Part II: therapeutic implications for oncology. J. Neuroimmunol. 346 , 577312 (2020).

Moreno-Smith, M., Lutgendorf, S. K. & Sood, A. K. Impact of stress on cancer metastasis. Future Oncol. 6 , 1863–1881 (2010).

Selye, H. The Stress of Life (McGraw-Hill, 1956).

Cacioppo, J. T., Cacioppo, S., Capitanio, J. P. & Cole, S. W. The neuroendocrinology of social isolation. Annu. Rev. Psychol. 66 , 733–767 (2015).

Bortolato, B. et al. Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat. Rev. 52 , 58–70 (2017).

Liu, R. T. & Alloy, L. B. Stress generation in depression: a systematic review of the empirical literature and recommendations for future study. Clin. Psychol. Rev. 30 , 582–593 (2010).

Wang, Q., Timberlake, M. A. II, Prall, K. & Dwivedi, Y. The recent progress in animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 77 , 99–109 (2017).

Sapolsky, R. M. Stress and the brain: individual variability and the inverted-U. Nat. Neurosci. 18 , 1344 (2015).

McEwen, B. S. Neurobiological and systemic effects of chronic stress. Chronic Stress 1 , 2470547017692328 (2017).

Article   PubMed Central   Google Scholar  

McEwen, B. S. & Stellar, E. Stress and the individual: mechanisms leading to disease. Arch. Intern. Med. 153 , 2093–2101 (1993).

McEwen, B. S. & Gianaros, P. J. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann. NY Acad. Sci. 1186 , 190 (2010).

Lazarus, R. S. & Folkman, S. Stress, Appraisal, and Coping (Springer, 1984).

Holmes, T. H. & Rahe, R. H. The social readjustment rating scale. J. Psychosom. Res. 11 , 213–218 (1967).

McEwen, B. S., Gray, J. D. & Nasca, C. Recognizing resilience: learning from the effects of stress on the brain. Neurobiol. Stress. 1 , 1–11 (2015).

Fava, G. A. et al. Clinical characterization of allostatic overload. Psychoneuroendocrinology 108 , 94–101 (2019).

Kiecolt-Glaser, J. K., Renna, M. E., Shrout, M. R. & Madison, A. A. Stress reactivity: what pushes us higher, faster, and longer — and why it matters. Curr. Dir. Psychol.Sci. 29 , 492–498 (2020).

Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144 , 646–674 (2011).

Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7 , 1016 (2017).

CAS   PubMed   PubMed Central   Google Scholar  

Manjili, M. H. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. Cancer Res. 77 , 2564–2569 (2017).

Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 , 401–410 (2003).

Patidar, A. et al. DAMP–TLR–cytokine axis dictates the fate of tumor. Cytokine 104 , 114–123 (2018).

Melamed, R. et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 19 , 114–126 (2005).

Melamed, R. et al. The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells. J. Immunother. 33 , 16–29 (2010).

Sorski, L. et al. Prevention of liver metastases through perioperative acute CpG-C immune stimulation. Cancer Immunol. Immunother. 69 , 2021–2031 (2020).

Strilic, B. & Offermanns, S. Intravascular survival and extravasation of tumor cells. Cancer Cell 32 , 282–293 (2017).

Shaashua, L. et al. Spontaneous regression of micro-metastases following primary tumor excision: a critical role for primary tumor secretome. BMC Biol. 18 , 1–13 (2020).

CAS   Google Scholar  

Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32 , 1267–1284 (2018).

Rosenne, E. et al. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav. Immun. 21 , 395–408 (2007).

Ben-Eliyahu, S., Shakhar, G., Page, G. G., Stefanski, V. & Shakhar, K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and β-adrenoceptors. Neuroimmunomodulation 8 , 154–164 (2000).

Sloan, E. K. et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70 , 7042–7052 (2010). This preclinical study in a breast cancer model reports that whereas chronic stress does not promote primary tumour growth, it promotes its metastatic dissemination, demonstrating specific interactions between stress and unique stages in cancer progression .

Du, P. et al. Chronic stress promotes EMT-mediated metastasis through activation of STAT3 signaling pathway by miR-337-3p in breast cancer. Cell Death Dis. 11 , 1–13 (2020).

Article   CAS   Google Scholar  

Madden, K. S., Szpunar, M. J. & Brown, E. B. Early impact of social isolation and breast tumor progression in mice. Brain Behav. Immun. 30 , S135–S141 (2013).

Volden, P. A. & Conzen, S. D. The influence of glucocorticoid signaling on tumor progression. Brain Behav. Immun. 30 , S26–S31 (2013).

Flint, M. S., Baum, A., Chambers, W. H. & Jenkins, F. J. Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones. Psychoneuroendocrinology 32 , 470–479 (2007).

Hara, M. R. et al. A stress response pathway regulates DNA damage through β 2 -adrenoreceptors and β-arrestin-1. Nature 477 , 349–353 (2011).

Hara, M. R., Sachs, B. D., Caron, M. G. & Lefkowitz, R. J. Pharmacological blockade of a β 2 AR–β-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. Cell Cycle 12 , 219–224 (2013).

Feng, Z. et al. Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proc. Natl Acad. Sci. USA 109 , 7013–7018 (2012).

Gidron, Y., Russ, K., Tissarchondou, H. & Warner, J. The relation between psychological factors and DNA-damage: a critical review. Biol. Psychol. 72 , 291–304 (2006).

Lamboy-Caraballo, R. et al. Norepinephrine-induced DNA damage in ovarian cancer cells. Int. J. Mol. Sci. 21 , 2250 (2020).

Article   CAS   PubMed Central   Google Scholar  

Flaherty, R. L. et al. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. Breast Cancer Res. 19 , 1–13 (2017).

Reeder, A. et al. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. Br. J. Cancer 112 , 1461–1470 (2015).

Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4 , e609–e616 (2016).

de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8 , e180–e190 (2020).

Antoni, M. H. et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer 6 , 240–248 (2006).

Irwin, M. R. & Cole, S. W. Reciprocal regulation of the neural and innate immune systems. Nat. Rev. Immunol. 11 , 625–632 (2011).

Collado-Hidalgo, A., Sung, C. & Cole, S. Adrenergic inhibition of innate anti-viral response: PKA blockade of type I interferon gene transcription mediates catecholamine support for HIV-1 replication. Brain Behav. Immun. 20 , 552–563 (2006).

Cacioppo, J. T. et al. Autonomic and glucocorticoid associations with the steady-state expression of latent Epstein–Barr virus. Hormones Behav. 42 , 32–41 (2002).

Glaser, R. et al. The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point. Brain Behav. Immun. 13 , 240–251 (1999).

Fang, C. Y. et al. Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia. Ann. Behav. Med. 35 , 87–96 (2008).

Fang, F. et al. Risk of infection-related cancers after the loss of a child: a follow-up study in Sweden. Cancer Res. 71 , 116–122 (2011).

Saul, A. N. et al. Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst. 97 , 1760–1767 (2005).

Sumis, A. et al. Social isolation induces autophagy in the mouse mammary gland: link to increased mammary cancer risk. Endocr. Relat. Cancer 23 , 839–856 (2016).

Kokolus, K. M. et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc. Natl Acad. Sci. USA 110 , 20176–20181 (2013).

Renz, B. W. et al. β 2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 33 , 75–90.e7 (2018). This research demonstrates the reciprocal relations between the malignant tissue and its direct sympathetic innervation in preclinical pancreatic cancer models .

Magnon, C. et al. Autonomic nerve development contributes to prostate cancer progression. Science 341 , 1236361 (2013).

Hermes, G. L. et al. Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc. Natl Acad. Sci. USA 106 , 22393–22398 (2009).

Hasen, N. S., O’Leary, K. A., Auger, A. P. & Schuler, L. A. Social isolation reduces mammary development, tumor incidence, and expression of epigenetic regulators in wild-type and p53-heterozygotic mice. Cancer Prev. Res. 3 , 620–629 (2010).

Nguyen, K. D. et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480 , 104–108 (2011).

Flierl, M. A. et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449 , 721–725 (2007).

Wong, H. P. S. et al. Nicotine promotes cell proliferation via α7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol. Appl. Pharmacol. 221 , 261–267 (2007).

Shi, M. et al. The β 2 -adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res. Treat. 125 , 351–362 (2011).

Amaro, F. et al. β-Adrenoceptor activation in breast MCF-10A cells induces a pattern of catecholamine production similar to that of tumorigenic MCF-7 cells. Int. J. Mol. Sci. 21 , 7968 (2020).

Zhang, X. et al. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 10 , 1–15 (2019).

Zhi, X. et al. Adrenergic modulation of AMPK-dependent autophagy by chronic stress enhances cell proliferation and survival in gastric cancer. Int. J. Oncol. 54 , 1625–1638 (2019).

Wong, H. P. et al. Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci. 88 , 1108–1112 (2011).

Sood, A. K. et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 120 , 1515–1523 (2010).

Liu, H. et al. Activation of adrenergic receptor β 2 promotes tumor progression and epithelial mesenchymal transition in tongue squamous cell carcinoma. Int. J. Mol. Med. 41 , 147–154 (2018).

Nagaraja, A. S. et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE 2 synthesis. Oncogene 35 , 2390–2397 (2016).

Kim-Fuchs, C. et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for β-adrenergic signaling in the pancreatic microenvironment. Brain Behav. Immun. 40 , 40–47 (2014).

Moretti, S. et al. β-Adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab. Invest. 93 , 279–290 (2013).

Pu, J. et al. Adrenaline promotes epithelial-to-mesenchymal transition via HuR–TGFβ regulatory axis in pancreatic cancer cells and the implication in cancer prognosis. Biochem. Biophys. Res. Commun. 493 , 1273–1279 (2017).

Liu, J. et al. A novel β 2 -AR/YB-1/β-catenin axis mediates chronic stress-associated metastasis in hepatocellular carcinoma. Oncogenesis 9 , 1–14 (2020).

Bucsek, M. J. et al. β-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8 + T cells and undermines checkpoint inhibitor therapy. Cancer Res. 77 , 5639–5651 (2017).

Chen, H. et al. Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre-metastatic niche through activating β-adrenergic signaling. J. Pathol. 244 , 49–60 (2018).

Lamkin, D. M. et al. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav. Immun. 26 , 635–641 (2012).

Thaker, P. H. et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12 , 939–944 (2006). This is the first preclinical study to demonstrate the effects of chronic stress on tumour angiogenesis, which also identifies the mediating adrenergic signalling pathway .

Chang, A. et al. β 2 -Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer. Brain Behav. Immun. 57 , 106–115 (2016).

Zahalka, A. H. & Frenette, P. S. Nerves in cancer. Nat. Rev. Cancer 20 , 143–157 (2020).

Qin, J.-f et al. Adrenergic receptor β 2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep. 48 , 295 (2015).

Lutgendorf, S. K. et al. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav. Immun. 25 , 250–255 (2011).

Yang, H. et al. Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity. Nat. Med. 25 , 1428–1441 (2019). This preclinical study conducted in several cancer models identifies a novel stress-induced mechanism, mediated though glucocorticoid signalling in dendritic cells, that can compromise chemotherapy-induced and immunotherapy-induced antitumour immunity .

Obradović, M. M. et al. Glucocorticoids promote breast cancer metastasis. Nature 567 , 540–544 (2019). This preclinical study uses several models of breast cancer to demonstrate that the activation of GR in breast cancer cells, through ROR1 kinase signalling, leads to increased metastasis and resistance to chemotherapy, thus emphasizing that GR signalling, either by endogenous (stress-induced) or exogenous sources of glucocorticoids, can worsen cancer progression .

Pan, D., Kocherginsky, M. & Conzen, S. D. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 71 , 6360–6370 (2011).

Madden, K. S., Szpunar, M. J. & Brown, E. B. β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res. Treat. 130 , 747–758 (2011).

Lutgendorf, S. K. et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 9 , 4514–4521 (2003).

Yang, E. V. et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav. Immun. 23 , 267–275 (2009).

Chen, H. et al. Adrenergic signaling promotes angiogenesis through endothelial cell–tumor cell crosstalk. Endocr. Relat. Cancer 21 , 783–795 (2014).

Shan, T. et al. β2-AR–HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Curr. Mol. Med. 13 , 1023–1034 (2013).

Xu, P. et al. Surgical trauma contributes to progression of colon cancer by downregulating CXCL4 and recruiting MDSCs. Exp. Cell Res. 370 , 692–698 (2018).

Budiu, R. A. et al. Restraint and social isolation stressors differentially regulate adaptive immunity and tumor angiogenesis in a breast cancer mouse model. Cancer Clin. Oncol. 6 , 12 (2017).

Hulsurkar, M. et al. β-Adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. Oncogene 36 , 1525–1536 (2017).

Lutgendorf, S. K. et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 95 , 808–815 (2002).

Lutgendorf, S. K. et al. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin. Cancer Res. 14 , 6839–6846 (2008).

Costanzo, E. S. et al. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104 , 305–313 (2005).

Lutgendorf, S. K. et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 26 , 4820–4827 (2008).

Stacker, S. A. et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer 14 , 159–172 (2014).

Le, C. P. et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat. Commun. 7 , 10634 (2016). This preclinical study demonstrates the effects of chronic stress on lymphatic modulation and metastasis, and identifies the underlying adrenergic mechanisms .

Bower, J. E. et al. Prometastatic molecular profiles in breast tumors from socially isolated women. JNCI Cancer Spectr. 2 , pky029 (2018).

Qiao, G., Chen, M., Bucsek, M. J., Repasky, E. A. & Hylander, B. L. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front. Immunol. 9 , 164 (2018).

Article   PubMed   PubMed Central   CAS   Google Scholar  

Hirata, T. & Narumiya, S. (2012). in Advances in Immunology (ed. Alt, F. W.) 143–174 (Elvesier, 2012)

Shakhar, G. & Ben-Eliyahu, S. In vivo β-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 160 , 3251–3258 (1998).

Inbar, S. et al. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E 2 through reduced NK activity. PLoS ONE 6 , e19246 (2011).

Rosenne, E. et al. In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav. Immun. 37 , 207–219 (2014).

Lutgendorf, S. K. et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J. Clin. Oncol. 23 , 7105–7113 (2005).

Hou, N. et al. A novel chronic stress-induced shift in the T H 1 to T H 2 response promotes colon cancer growth. Biochem. Biophys. Res. Commun. 439 , 471–476 (2013).

Lutgendorf, S. K. et al. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav. Immun. 22 , 890–900 (2008).

Mohammadpour, H. et al. β 2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J. Clin. Invest. 129 , 5537–5552 (2019).

Mundy-Bosse, B. L., Thornton, L. M., Yang, H.-C., Andersen, B. L. & Carson, W. E. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell. Immunol. 270 , 80–87 (2011).

Armaiz-Pena, G. N. et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget 6 , 4266–4273 (2015).

Lamkin, D. M. et al. β-Adrenergic-stimulated macrophages: comprehensive localization in the M1–M2 spectrum. Brain Behav. Immun. 57 , 338–346 (2016).

Campbell, J. P. et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 10 , e1001363 (2012).

Simpson, C. D., Anyiwe, K. & Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett. 272 , 177–185 (2008).

Lutgendorf, S. K. et al. Epithelial–mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer 126 , 4407–4413 (2020).

Benish, M. et al. Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 15 , 2042–2052 (2008).

Kaira, K. et al. Prognostic impact of β 2 adrenergic receptor expression in surgically resected pulmonary pleomorphic carcinoma. Anticancer. Res. 39 , 395–403 (2019).

Choy, C. et al. Inhibition of β 2 -adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncol. Rep. 35 , 3135–3142 (2016).

Al-Niaimi, A. et al. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecol. Oncol. 143 , 521–525 (2016).

Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visvanathan, K. β blockers and breast cancer mortality: a population-based study. J. Clin. Oncol. 29 , 2635–2644 (2011).

Lemeshow, S. et al. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol. Biomarkers Prev. 20 , 2273–2279 (2011).

Cata, J. P. et al. Perioperative β-blocker use and survival in lung cancer patients. J. Clin. Anesth. 26 , 106–117 (2014).

Heitz, F. et al. Intake of selective β blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol. Oncol. 144 , 181–186 (2017).

Matzner, P. et al. Deleterious synergistic effects of distress and surgery on cancer metastasis: abolishment through an integrated perioperative immune-stimulating stress-inflammatory-reducing intervention. Brain Behav. Immun. 80 , 170–178 (2019).

Stefanski, V. & Ben-Eliyahu, S. Social confrontation and tumor metastasis in rats: defeat and β-adrenergic mechanisms. Physiol. Behav. 60 , 277–282 (1996).

Dhabhar, F. S. et al. Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma. Brain Behav. Immun. 24 , 127–137 (2010).

Benaroya-Milshtein, N., Hollander, N., Apter, A., Yaniv, I. & Pick, C. G. Stress conditioning in mice: alterations in immunity and tumor growth. Stress 14 , 301–311 (2011).

Williams, J. B. et al. A model of gene–environment interaction reveals altered mammary gland gene expression and increased tumor growth following social isolation. Cancer Prev. Res. 2 , 850–861 (2009).

Dawes, R. P. et al. Chronic stress exposure suppresses mammary tumor growth and reduces circulating exosome TGF-β content via β-adrenergic receptor signaling in MMTV-PyMT mice. Breast Cancer 14 , 1178223420931511 (2020).

PubMed   PubMed Central   Google Scholar  

Huo, J. et al. Bone marrow-derived mesenchymal stem cells promoted cutaneous wound healing by regulating keratinocyte migration via β 2 -adrenergic receptor signaling. Mol. Pharmaceutics 15 , 2513–2527 (2018).

Ren, H. et al. Inhibition of α 1 -adrenoceptor reduces TGF-β1-induced epithelial-to-mesenchymal transition and attenuates UUO-induced renal fibrosis in mice. FASEB J. 34 , 14892–14904 (2020).

Panina-Bordignon, P. et al. β 2 -agonists prevent T H 1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100 , 1513–1519 (1997).

Ağaç, D., Estrada, L. D., Maples, R., Hooper, L. V. & Farrar, J. D. The β 2 -adrenergic receptor controls inflammation by driving rapid IL-10 secretion. Brain Behav. Immun. 74 , 176–185 (2018).

Kavelaars, A., Van De Pol, M., Zijlstra, J. & Heijnen, C. J. β 2 -Adrenergic activation enhances interleukin-8 production by human monocytes. J. Neuroimmunol. 77 , 211–216 (1997).

Steinle, J. J., Cappocia, F. C. Jr & Jiang, Y. β-Adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells. Growth Factors 26 , 325–330 (2008).

Asano, A., Morimatsu, M., Nikami, H., Yoshida, T. & Saito, M. Adrenergic activation of vascular endothelial growth factor mRNA expression in rat brown adipose tissue: implication in cold-induced angiogenesis. Biochem. J. 328 , 179–183 (1997).

Chida, Y., Hamer, M., Wardle, J. & Steptoe, A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat. Clin. Pract. Oncol. 5 , 466–475 (2008). This paper is the most comprehensive meta-analysis assessing the contribution of psychosocial stress to cancer incidence, survival and mortality in several human malignancies .

Coyne, J. C., Ranchor, A. V. & Palmer, S. C. Meta-analysis of stress-related factors in cancer. Nat. Rev. Clin. Oncol. 7 , 1–2 (2010).

Article   Google Scholar  

Mravec, B. & Tibensky, M. Increased cancer incidence in “cold” countries: an (un)sympathetic connection? J. Therm. Biol. 89 , 102538 (2020).

Keinan-Boker, L., Vin-Raviv, N., Liphshitz, I., Linn, S. & Barchana, M. Cancer incidence in Israeli Jewish survivors of World War II. J. Natl Cancer Inst. 101 , 1489–1500 (2009).

Huang, T. et al. Depression and risk of epithelial ovarian cancer: results from two large prospective cohort studies. Gynecol. Oncol. 139 , 481–486 (2015).

Schoemaker, M. J. et al. Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom. Breast Cancer Res. 18 , 72 (2016).

Trudel-Fitzgerald, C. et al. The association of work characteristics with ovarian cancer risk and mortality. Psychosom. Med. 79 , 1059 (2017).

Liang, J.-A. et al. The analysis of depression and subsequent cancer risk in Taiwan. Cancer Epidemiol. Prev. Biomarkers 20 , 473–475 (2011).

Heikkilä, K. et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116 000 European men and women. BMJ 346 , f165 (2013).

Yang, T. et al. Work stress and the risk of cancer: a meta-analysis of observational studies. Int. J. Cancer 144 , 2390–2400 (2019).

Perego, M. et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci. Transl Med. 12 , eabb5817 (2020). This preclinical study identifies a distinct mechanism by which tumour-associated neutrophils respond to stress-induced adrenergic activation, and lead to reactivation of dormant tumour cells. This study highlights β-blockade as a potential strategy to prevent stress-induced cancer relapse .

Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl Med. 10 , eaan3464 (2018).

Decker, A. M. et al. Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow. Mol. Cancer Res. 15 , 1644–1655 (2017).

Gil, F., Costa, G., Hilker, I. & Benito, L. First anxiety, afterwards depression: psychological distress in cancer patients at diagnosis and after medical treatment. Stress. Health 28 , 362–367 (2012).

Carlson, L. et al. High levels of untreated distress and fatigue in cancer patients. Br. J. Cancer 90 , 2297–2304 (2004).

Wang, X. et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol. Psychiatry 25 , 3186–3197 (2020).

Pinquart, M. & Duberstein, P. Depression and cancer mortality: a meta-analysis. Psychol. Med. 40 , 1797 (2010).

Pinquart, M. & Duberstein, P. R. Associations of social networks with cancer mortality: a meta-analysis. Crit. Rev. Oncol. Hematol. 75 , 122–137 (2010).

Cohen, L. et al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS ONE 7 , e42324 (2012).

Lutgendorf, S. K. et al. Social influences on clinical outcomes of patients with ovarian cancer. J. Clin. Oncol. 30 , 2885 (2012).

Chou, A. F., Stewart, S. L., Wild, R. C. & Bloom, J. R. Social support and survival in young women with breast carcinoma. Psychooncology 21 , 125–133 (2012).

Kroenke, C. H. et al. Prediagnosis social support, social integration, living status, and colorectal cancer mortality in postmenopausal women from the women’s health initiative. Cancer 126 , 1766–1775 (2020).

Fagundes, C. P. et al. Basal cell carcinoma: stressful life events and the tumor environment. Arch. Gen. Psychiatry 69 , 618–626 (2012).

Armer, J. S. et al. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124 , 3401–3408 (2018).

Mirosevic, S. et al. “Not just another meta-analysis”: sources of heterogeneity in psychosocial treatment effect on cancer survival. Cancer Med. 8 , 363–373 (2019). This meta-analysis assesses the effects of psychosocial stress management on cancer survival, discusses limitations of meta-analytic methods and identifies subpopulations that may better benefit from stress-management approaches .

Fu, W. W. et al. The impact of psychosocial intervention on survival in cancer: a meta-analysis. Ann. Palliat. Med. 5 , 93–106 (2016).

Xia, Y. et al. Psychosocial and behavioral interventions and cancer patient survival again: hints of an adjusted meta-analysis. Integr. Cancer Therapies 13 , 301–309 (2014).

Oh, P., Shin, S., Ahn, H. S. & Kim, H. Meta-analysis of psychosocial interventions on survival time in patients with cancer. Psychol. Health 31 , 396–419 (2016).

Andersen, B. L. et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J. Clin. Oncol. 22 , 3570 (2004).

Fawzy, F. I. et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch. Gen. Psychiatry 47 , 720–725 (1990).

Antoni, M. H. et al. Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics. Biol. Psychiatry 71 , 366–372 (2012).

Fawzy, F. I. & Fawzy, N. W. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch. Gen. Psychiatry 60 , 100–103 (2003).

Stefanek, M. E., Palmer, S. C., Thombs, B. D. & Coyne, J. C. Finding what is not there: unwarranted claims of an effect of psychosocial intervention on recurrence and survival. Cancer 115 , 5612–5616 (2009).

Coyne, J. C. & Tennen, H. Positive psychology in cancer care: bad science, exaggerated claims, and unproven medicine. Ann. Behav. Med. 39 , 16–26 (2010).

Coyne, J. C., Stefanek, M. & Palmer, S. C. Psychotherapy and survival in cancer: the conflict between hope and evidence. Psychol. Bull. 133 , 367 (2007).

Kraemer, H. C., Kuchler, T. & Spiegel, D. Use and misuse of the consolidated standards of reporting trials (CONSORT) guidelines to assess research findings: comment on Coyne, Stefanek, and Palmer (2007). Psychol. Bull. 135 , 173–178 (2009).

Spiegel, D., Bloom, J. R., Kraemer, H. C. & Gottheil, E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2 , 888–891 (1989).

Spiegel, D. et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 110 , 1130–1138 (2007).

Goodwin, P. J. et al. The effect of group psychosocial support on survival in metastatic breast cancer. N. Engl. J. Med. 345 , 1719–1726 (2001).

Boesen, E. H. et al. Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J. Clin. Oncol. 25 , 5698–5703 (2007).

Ben-Eliyahu, S. Tumor excision as a metastatic russian roulette: perioperative interventions to improve long-term survival of cancer patients. Trends Cancer 6 , 951–959 (2020).

Burton, M. V. et al. A randomized controlled trial of preoperative psychological preparation for mastectomy. Psychooncology 4 , 1–19 (1995).

Kuchler, T., Bestmann, B., Rappat, S., Henne-Bruns, D. & Wood-Dauphinee, S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J. Clin. Oncol. 25 , 2702–2708 (2007).

Zhang, X.-D. et al. Perioperative comprehensive supportive care interventions for Chinese patients with esophageal carcinoma: a prospective study. Asian Pac. J. Cancer Prev. 14 , 7359–7366 (2013).

Shaashua, L. et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin. Cancer Res. 23 , 4651–4661 (2017). This study is the first clinical trial in patients with cancer to assess perioperative safety and efficacy of the combined use of propranolol and etodolac on biomarkers related to breast cancer progression .

Benjamin, B. et al. Effect of β blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int. J. Colorectal Dis. 25 , 1459–1464 (2010).

Hazut, O. et al. The effect of β-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int. J. Clin. Pharmacol. Ther. 49 , 545–554 (2011).

Hiller, J. G. et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clin. Cancer Res. 26 , 1803–1811 (2020).

Jang, H. I., Lim, S. H., Lee, Y. Y., Kim, T. J. & Choi, C. H. Perioperative administration of propranolol to women undergoing ovarian cancer surgery: a pilot study. Obstet. Gynecol. Sci. 60 , 170–177 (2017).

Knight, J. M. et al. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 4 , 467–476 (2020).

Gandhi, S. et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin. Cancer Res. 27 , 87–95 (2021).

Ricon, I., Hanalis-Miller, T., Haldar, R., Jacoby, R. & Ben-Eliyahu, S. Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of β-adrenergic and cyclooxygenase 2 signaling. Cancer 125 , 45–56 (2019).

Horowitz, M., Neeman, E., Sharon, E. & Ben-Eliyahu, S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 12 , 213–226 (2015). This review summarizes important aspects within the perioperative period that make this time frame critical in affecting long-term cancer outcomes, and suggests potential clinical perioperative interventions to reduce metastatic disease .

Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B. & Sloan, E. K. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 15 , 205–218 (2018). This review highlights perioperative events as critical in affecting cancer outcomes and suggests how to reduce perioperative risks .

Sorski, L. et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition. Brain Behav. Immun. 58 , 91–98 (2016).

Glasner, A. et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184 , 2449–2457 (2010). This preclinical study demonstrates the synergistic beneficial effects of perioperative blockade of adrenergic and prostaglandin signalling on immunity and postoperative survival in two models of spontaneous metastasis .

Haldar, R. et al. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav. Immun. 73 , 294–309 (2018).

Haldar, R. et al. Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: a randomized controlled trial. Cancer 126 , 3991–4001 (2020). This clinical trial demonstrates safety, feasibility and efficacy of perioperative combined treatment with propranolol and etodolac to improve cancer biomarkers and, potentially, survival outcomes in patients with CRC .

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03838029 (2019).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03919461 (2019).

Busby, J., Mills, K., Zhang, S.-D., Liberante, F. G. & Cardwell, C. R. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res. 20 , 4 (2018).

Boursi, B., Lurie, I., Haynes, K., Mamtani, R. & Yang, Y.-X. Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients. Eur. J. Cancer Care 27 , e12666 (2018).

Zingone, A. et al. Relationship between anti-depressant use and lung cancer survival. Cancer Treat. Res. Commun. 10 , 33–39 (2017).

Stockler, M. R. et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 8 , 603–612 (2007).

Sternbach, H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J. Clin. Psychiatry 64 , 1153–1162 (2003).

Grygier, B. et al. Inhibitory effect of antidepressants on B16F10 melanoma tumor growth. Pharmacol. Rep. 65 , 672–681 (2013).

Kubera, M. et al. Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice. J. Neuroimmunol. 240–241 , 34–44 (2011).

Andersen, B. L., Shapiro, C. L., Farrar, W. B., Crespin, T. & Wells-DiGregorio, S. Psychological responses to cancer recurrence: a controlled prospective study. Cancer 104 , 1540–1547 (2005).

Linden, W., Vodermaier, A., MacKenzie, R. & Greig, D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J. Affect. Disord. 141 , 343–351 (2012).

Mitchell, A. J., Ferguson, D. W., Gill, J., Paul, J. & Symonds, P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 14 , 721–732 (2013).

Watts, S., Prescott, P., Mason, J., McLeod, N. & Lewith, G. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 5 , e007618 (2015).

Sephton, S. E. et al. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23 , 1148–1155 (2009).

Andersen, B. L. et al. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90 , 30–36 (1998).

Blomberg, B. B. et al. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J. Psychosom. Res. 67 , 369–376 (2009).

Schrepf, A. et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav. Immun. 30 , S126–S134 (2013).

Pyter, L. M., Pineros, V., Galang, J. A., McClintock, M. K. & Prendergast, B. J. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic–pituitary–adrenal axis regulation. Proc. Natl Acad. Sci. USA 106 , 9069–9074 (2009).

Bower, J. E. & Lamkin, D. M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 30 , S48–S57 (2013).

Bower, J. E. et al. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J. Clin. Oncol. 29 , 3517 (2011).

Norden, D. M. et al. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function. Brain Behav. Immun. 43 , 76–85 (2015).

Vardy, J. L. et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J. Clin. Oncol. 33 , 4085 (2015).

Hutchinson, A. D., Hosking, J. R., Kichenadasse, G., Mattiske, J. K. & Wilson, C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat. Rev. 38 , 926–934 (2012).

Chrousos, G. P. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332 , 1351–1363 (1995).

Ben-Shaanan, T. L. et al. Modulation of anti-tumor immunity by the brain’s reward system. Nat. Commun. 9 , 2723 (2018).

Matzner, P. et al. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat. Rev. Clin. Oncol. 17 , 313–326 (2020).

Goldfarb, Y. et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann. Surg. 253 , 798–810 (2011).

Levi, B. et al. Stress impairs the efficacy of immune stimulation by CpG-C: potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period. Brain Behav. Immun. 56 , 209–220 (2016).

Shaashua, L. et al. Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids. Psychoneuroendocrinology 42 , 11–23 (2014).

Sommershof, A., Scheuermann, L., Koerner, J. & Groettrup, M. Chronic stress suppresses anti-tumor T CD8 + responses and tumor regression following cancer immunotherapy in a mouse model of melanoma. Brain Behav. Immun. 65 , 140–149 (2017).

Nissen, M. D., Sloan, E. K. & Mattarollo, S. R. β-adrenergic signaling impairs antitumor CD8 + T-cell responses to B-cell lymphoma immunotherapy. Cancer Immunol. Res. 6 , 98–109 (2018).

Kang, Y. et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clin. Cancer Res. 22 , 1713–1724 (2016).

Deng, G.-H. et al. Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. J. Exp. Clin. Cancer Res. 33 , 21 (2014).

Liu, J. et al. The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models. Psychoneuroendocrinology 52 , 130–142 (2015).

Hassan, S. et al. β 2 -Adrenoreceptor signaling increases therapy resistance in prostate cancer by upregulating MCL1. Mol. Cancer Res. 18 , 1839–1848 (2020).

Eng, J. W.-L. et al. Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β 2 -adrenergic receptor activation. Nat. Commun. 6 , 6426 (2015). This preclinical study in pancreatic cancer models demonstrates that the ambient housing temperature of laboratory mice can cause chronic adrenergic stress, which in turn can lead to resistance to cytotoxic therapies, but this effect can be reversed by blockade of β-adrenergic signalling. This study supports the potential beneficial effects of β-blockade in the context of cancer therapy .

Chen, M. et al. Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation. Nat. Commun. 11 , 1821 (2020).

Shi, M. et al. Catecholamine-induced β 2 -adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J. Immunol. 190 , 5600–5608 (2013).

Liu, D. et al. β 2 -AR signaling controls trastuzumab resistance-dependent pathway. Oncogene 35 , 47–58 (2016).

Zhang, C. et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol. Ther. 6 , 278–287 (2007).

Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155 , 1309–1322 (2013).

Skor, M. N. et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin. Cancer Res. 19 , 6163–6172 (2013).

Zhang, C. et al. Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int. J. Oncol. 29 , 1295–1301 (2006). This comprehensive screen identifies glucocorticoid-induced chemotherapy resistance in numerous human carcinoma cell lines .

Fiala, O. et al. Incidental use of β-blockers is associated with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: a single-institution retrospective analysis of 514 patients. Cancers 11 , 1856 (2019).

Chaudhary, K. R. et al. Effects of β-adrenergic antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer. J. Clin. Med. 8 , 575 (2019).

Wang, H. et al. Improved survival outcomes with the incidental use of β-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann. Oncol. 24 , 1312–1319 (2013).

Kokolus, K. M. et al. β blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 7 , e1405205 (2018).

Navari, R. M. & Aapro, M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 374 , 1356–1367 (2016).

Pufall, M. A. in Glucocorticoid Signaling (eds Wang, J. C. & Harris, C.) 315–333 (Springer, 2015).

Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13 , 473–486 (2016).

Arbour, K. C. et al. Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. J. Clin. Oncol. 36 , 2872–2878 (2018). This retrospective study in patients with non-small-cell lung cancer reports an association between the use of high-dose corticosteroids, reduced efficacy of immune checkpoint inhibitor therapy and poorer clinical outcome, emphasizing the importance of reassessing the prevalent use of synthetic glucocorticoids in patients with cancer .

Scott, S. C. & Pennell, N. A. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J. Thorac. Oncol. 13 , 1771–1775 (2018).

Fucà, G. et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4 , e000457 (2019).

Kissane, D. W. et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J. Clin. Oncol. 22 , 4255–4260 (2004).

Andersen, B. L. et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 113 , 3450–3458 (2008).

Boesen, E. H. et al. Psychosocial group intervention for patients with primary breast cancer: a randomised trial. Eur. J. Cancer 47 , 1363–1372 (2011).

Stagl, J. M. et al. A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. Breast Cancer Res. Treat. 154 , 319–328 (2015).

Cunningham, A. et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 7 , 508–517 (1998).

Edelman, S., Lemon, J., Bell, D. R. & Kidman, A. D. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 8 , 474–481 (1999).

Kissane, D. W. et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 16 , 277–286 (2007).

Andersen, B. L. et al. Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin. Cancer Res. 16 , 3270–3278 (2010).

Linn, M. W., Linn, B. S. & Harris, R. Effects of counseling for late stage cancer patients. Cancer 49 , 1048–1055 (1982).

Ilnyckyj, A., Farber, J., Cheang, M. & Weinerman, B. A randomized controlled trial of psychotherapeutic intervention in cancer patients. Ann. R. Coll. Physicians Surg. Can. 27 , 93–96 (1994).

Google Scholar  

Ratcliffe, M. A., Dawson, A. A. & Walker, L. G. Eysenck personality inventory L-scores in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Psychooncology 4 , 39–45 (1995).

Ross, L. et al. No effect on survival of home psychosocial intervention in a randomized study of Danish colorectal cancer patients. Psychooncology 18 , 875–885 (2009).

Temel, J. S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363 , 733–742 (2010).

Guo, Z. et al. The benefits of psychosocial interventions for cancer patients undergoing radiotherapy. Health Qual. Life Outcomes 11 , 121 (2013).

Dhabhar, F. S. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol. Res. 58 , 193–210 (2014).

Viswanathan, K. & Dhabhar, F. S. Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc. Natl Acad. Sci. USA 102 , 5808–5813 (2005).

Neeman, E. et al. Stress and skin leukocyte trafficking as a dual-stage process. Brain Behav. Immun. 26 , 267–276 (2012).

Russell, G. & Lightman, S. The human stress response. Nat. Rev. Endocrinol. 15 , 525–534 (2019).

Cruz-Topete, D. & Cidlowski, J. A. One hormone, two actions: anti-and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 22 , 20–32 (2015).

Shaashua, L. et al. In vivo suppression of plasma IL-12 levels by acute and chronic stress paradigms: potential mediating mechanisms and sex differences. Brain Behav. Immun. 26 , 996–1005 (2012).

Baum, A., O’Keeffe, M. K. & Davidson, L. M. Acute stressors and chronic response: the case of traumatic stress 1. J. Appl. Soc. Psychol. 20 , 1643–1654 (1990).

Hawley, J. A., Hargreaves, M., Joyner, M. J. & Zierath, J. R. Integrative biology of exercise. Cell 159 , 738–749 (2014).

Neufer, P. D. et al. Understanding the cellular and molecular mechanisms of physical activity-induced health benefits. Cell Metab. 22 , 4–11 (2015).

Brownley, K. A. et al. Sympathoadrenergic mechanisms in reduced hemodynamic stress responses after exercise. Med. Sci. Sports Exerc. 35 , 978–986 (2003).

Traustadóttir, T., Bosch, P. R. & Matt, K. S. The HPA axis response to stress in women: effects of aging and fitness. Psychoneuroendocrinology 30 , 392–402 (2005).

Petersen, A. M. W. & Pedersen, B. K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 98 , 1154–1162 (2005).

Speck, R. M., Courneya, K. S., Mâsse, L. C., Duval, S. & Schmitz, K. H. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J. Cancer Surviv. 4 , 87–100 (2010).

Rogers, L. Q. et al. Effects of a multicomponent physical activity behavior change intervention on fatigue, anxiety, and depressive symptomatology in breast cancer survivors: randomized trial. Psychooncology 26 , 1901–1906 (2017).

Mehnert, A. et al. Effects of a physical exercise rehabilitation group program on anxiety, depression, body image, and health-related quality of life among breast cancer patients. Oncol. Res. Treat. 34 , 248–253 (2011).

Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S. & Keul, J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85 , 2273–2277 (1999).

McNeely, M. L. et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 175 , 34–41 (2006).

Kruijsen-Jaarsma, M., Révész, D., Bierings, M. B., Buffart, L. M. & Takken, T. Effects of exercise on immune function in patients with cancer: a systematic review. Exerc. Immunol. Rev. 19 , 120–143 (2013).

PubMed   Google Scholar  

Davies, N., Batehup, L. & Thomas, R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br. J. Cancer 105 , S52–S73 (2011).

Stout, N. L., Baima, J., Swisher, A. K., Winters-Stone, K. M. & Welsh, J. A systematic review of exercise systematic reviews in the cancer literature (2005–2017). PMR 9 , S347–S384 (2017).

Hanns, P., Paczulla, A. M., Medinger, M., Konantz, M. & Lengerke, C. Stress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis. Cell Stress. 3 , 221 (2019).

Dethlefsen, C. et al. Exercise-induced catecholamines activate the hippo tumor suppressor pathway to reduce risks of breast cancer development. Cancer Res. 77 , 4894–4904 (2017).

Pedersen, L. et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 23 , 554–562 (2016).

Song, Y. et al. Enriching the housing environment for mice enhances their NK cell antitumor immunity via sympathetic nerve-dependent regulation of NKG2D and CCR5. Cancer Res. 77 , 1611–1622 (2017).

Graff, R. M. et al. β 2 -Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8 + T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav. Immun. 74 , 143–153 (2018).

Devalon, M. et al. DOPA in plasma increases during acute exercise and after exercise training. J. Lab. Clin. Med. 114 , 321–327 (1989).

Yamaguchi, K., Takagi, Y., Aoki, S., Futamura, M. & Saji, S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 232 , 58–65 (2000).

Hashimoto, M. et al. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact. Cardiovasc. Thorac. Surg. 18 , 775–783 (2014).

O’Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 , 277–285 (1997).

O’Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 , 315–328 (1994).

Abramovitch, R., Marikovsky, M., Meir, G. & Neeman, M. Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer 79 , 1392–1398 (1999).

Pascual, M. et al. Randomized clinical trial comparing inflammatory and angiogenic response after open versus laparoscopic curative resection for colonic cancer. Br. J. Surg. 98 , 50–59 (2011).

Garssen, B., Boomsma, M. F. & Beelen, R. H. Psychological factors in immunomodulation induced by cancer surgery: a review. Biol. Psychol. 85 , 1–13 (2010).

Cata, J. P. et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J. Anaesthesiol. Clin. Pharmacol. 33 , 317 (2017).

Lavon, H. et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br. J. Anaesth. 120 , 188–196 (2018).

Del Mastro, L. et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur. J. Cancer 38 , 359–366 (2002).

Vyas, D., Laput, G. & Vyas, A. K. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco. Targets Ther. 7 , 1015 (2014).

Shaked, Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat. Rev. Clin. Oncol. 13 , 611 (2016).

Antoni, M. H. et al. How stress management improves quality of life after treatment for breast cancer. J. Consul. Clin. Psychol. 74 , 1143 (2006).

Andersen, B. L. et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav. Immun. 21 , 953–961 (2007).

Riba, M. B. et al. Distress management, version 3.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 17 , 1229–1249 (2019).

Buffart, L. M. et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 12 , 1–21 (2012).

Bower, J. E. et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology 43 , 20–29 (2014).

Witek-Janusek, L. et al. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav. Immun. 22 , 969–981 (2008).

Bower, J. E. et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121 , 1231–1240 (2015).

Antoni, M. H. Stress Management Intervention for Women with Breast Cancer (American Psychological Association, 2003).

Antoni, M. H. et al. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav. Immun. 23 , 580–591 (2009).

Download references

Acknowledgements

The authors thank I. Ben-Ami Bartal for fruitful discussions and for critiques of the manuscript, and are grateful to the Emerson Collective, the Israel Cancer Research Fund and the Israel Science Foundation for their support.

Author information

Authors and affiliations.

Sagol School of Neuroscience and School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel

Anabel Eckerling, Itay Ricon-Becker, Liat Sorski, Elad Sandbank & Shamgar Ben-Eliyahu

You can also search for this author in PubMed   Google Scholar

Contributions

All authors researched data for the article, substantially contributed to discussion of content and wrote, reviewed and edited the manuscript before submission.

Corresponding author

Correspondence to Shamgar Ben-Eliyahu .

Ethics declarations

Competing interests.

The authors declare no competing interests.

Additional information

Peer review information.

Nature Reviews Cancer thanks E. Repasky, who co-reviewed with H. Mohammadpour, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

(SNS). Part of the autonomic nervous system that is involuntarily activated by stressors (for example, a dangerous or stressful situation) and orchestrates the ‘fight or flight’ response through adrenergic innervation of the adrenal medulla and of various organs (for example, the heart) through systemic and local release of adrenaline and noradrenaline, respectively.

A neuroendocrine system with negative feedback that increases systemic glucocorticoid (for example, cortisol) levels in various circumstances, including stressful conditions. Hypothalamic corticotropin-releasing hormone (CRH) elevates systemic release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, which triggers the release of glucocorticoids from the adrenal cortex, which also trigger negative feedback through the pituitary and hypothalamic levels.

Endogenous host-derived molecules that are released by damaged and dying cells. They are recognized by pattern recognition receptors on numerous cells, which lead to migration and activation of various immune cells and consequent innate and adaptive immune responses.

A family of molecules that are characterized by a catechol and an amine group in their chemical structure, and function as neurotransmitters and hormones within the body. These include dopamine, noradrenaline and adrenaline, all of which are synthesized from the amino acid tyrosine.

An experimental stress paradigm, where the animal is placed in a confined space (a tube-shaped apparatus perforated for air exchange) that prevents free movement but does not press or induce pain to the animal. Such restraint can last minutes to hours and can be repeated daily for several weeks as a chronic stress paradigm.

Refers to experimental methods for ablation of sympathetic nerves (also called sympathectomy), by either surgical cut of sympathetic nerve fibres or chemical ablation (for example, using 6-hydroxydopamine).

A class of cell surface G-protein-coupled receptors that bind different prostaglandins and are expressed on various cell types, including immune cells; for example, prostaglandin E 2 binds to the prostaglandin E 2 receptor 1–4 subtypes.

(T H 1 cell). A CD4 + T cell that participates in the pro-inflammatory type 1 or cellular immune response against intracellular pathogens and malignant cells. Naive T cells are differentiated into the type 1 phenotype following exposure to interleukin-12 (IL-12), and are known for the secretion of interferon-γ (IFNγ), which is also involved in the effector functions of cytotoxic T cells.

(T H 2 cell). A CD4 + T cell that participates in type 2 or humoral immune response against extracellular pathogens (for example, helminths) and allergens. Naive T cells are differentiated into a type 2 phenotype following exposure to interleukin-4 (IL-4), and are known for the secretion of IL-4, IL-13 and IL-5, and promotion of the production of antibodies.

A class of drugs with antagonistic activity towards β-adrenergic receptors (β-ARs). The drugs vary in specificity to the different β-ARs (β 1 -AR, β 2 -AR and β 3 -AR) and are classified as selective or non-selective to a certain receptor subtype.

An experimental stress paradigm in which the home cage of rodents is placed in a lit room in a 45° tilted position, starting before the onset of the animals’ dark period, resulting in reduced available floor space and disruption of the dark–light cycle.

An experimental stress paradigm where a weight is attached to the tail of rodents (usually rats, up to 2.5% of total body weight), which are then placed in a room temperature water tank for few minutes, followed by a rest period. This swim–rest cycle is usually repeated several times.

An experimental stress paradigm in which a midline abdominal incision is performed under anaesthesia, and often the small intestine is externalized and left hydrated in a soaked gauze pad for 30 min. The intestine is then internalized and the abdomen is sutured.

An experimental stress paradigm where an intruder rodent (a non-cage-mate animal) is introduced into a home cage populated with several stable cage-mates. The intruder is usually attacked by the residents cage-mates and/or displays submissive behaviour.

An experimental stress paradigm that is executed in an apparatus containing an electrified grid floor, in which the animal is exposed to electric shocks of varying intensity and duration. The paradigm can be acute or chronic, and is also used for fear-conditioning.

The ratio of the probability of events in a treatment group to the probability of events in a control group.

The tendency to publish a study based on its results (positive rather than negative findings or significant rather than non-significant findings). Existence of this bias can be statistically assessed in meta-analyses by Egger’s linear regression test.

A non-profit organization (maintaining no conflict of interests), which, among other activities, publishes methodologies and guidelines to produce high-quality systematic reviews and meta-analyses.

(CpG-C). A synthetic oligodeoxynucleotide (ODN) that functions as a Toll-like receptor 9 (TLR9) agonist and induces a physiological host-dependent activation of the immune system.

(GLA-SE). A synthetic agonist of Toll-like receptor 4 (TLR4). For administration, GLA is dissolved in an oil–water stable emulsion that serves as an adjuvant delivery system.

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Eckerling, A., Ricon-Becker, I., Sorski, L. et al. Stress and cancer: mechanisms, significance and future directions. Nat Rev Cancer 21 , 767–785 (2021). https://doi.org/10.1038/s41568-021-00395-5

Download citation

Accepted : 23 July 2021

Published : 10 September 2021

Issue Date : December 2021

DOI : https://doi.org/10.1038/s41568-021-00395-5

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

Association between allostatic load and breast cancer risk: a cohort study.

Breast Cancer Research (2023)

Chronic stress in solid tumor development: from mechanisms to interventions

  • Jiajing Yan
  • Yibing Chen
  • Zhengzhi Zou

Journal of Biomedical Science (2023)

Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling

  • Yifeng Zheng

Journal of Experimental & Clinical Cancer Research (2023)

Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop

  • Xiuping Zhou

Chronic stress induces pulmonary epithelial cells to produce acetylcholine that remodels lung pre-metastatic niche of breast cancer by enhancing NETosis

Quick links.

  • Explore articles by subject
  • Guide to authors
  • Editorial policies

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

cancer and its types research paper

  • Open access
  • Published: 02 January 2024

The current status of clinical trials on cancer and age disparities among the most common cancer trial participants

  • Shuang Zhao 1 ,
  • Miao Miao 1 ,
  • Qingqing Wang 1 ,
  • Haijuan Zhao 1 ,
  • Han Yang 1 &
  • Xin Wang 1  

BMC Cancer volume  24 , Article number:  30 ( 2024 ) Cite this article

288 Accesses

Metrics details

To illustrate the status of all cancer clinical trials and characterize clinical trial enrollment disparities in the most common cancer.

Clinical trial data were extracted from ClinicalTrials.gov website. All searched clinical trials were included in the current status analysis of clinical trials on cancer. Among all the clinical trials, only trials addressing single disease sites of breast, prostate, colorectal, or lung (BPCRL) cancer were included in the age disparities analysis. The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was calculated for each trial.

A total of 7747 clinical trials were included in the current status analysis of clinical trials on cancer. The number of registered trials had been increasing from 2008 to 2021 (AAPC = 50.60, 95% CI 36.60, 66.00, P  < 0.05). Of the 7747 trials, 1.50% (116) of the studies were clinical trials for the elderly aged 60 years or older. 322 trials were included in the age disparities analysis. For all trials, the median DMA was − 8.15 years ( P 25 , P 75 , − 10.83 to − 2.98 years, P  < 0.001). The median DMA were − 9.55 years ( P 25 , P 75 , − 11.63 to − 7.11 years), − 7.10 years ( P 25 , P 75 , − 9.80 to − 5.70 years), − 9.75 years ( P 25 , P 75 , − 11.93 to − 7.35 years), 3.50 years ( P 25 , P 75 , 0.60 to 4.55 years), respectively, for breast cancer, colorectal cancer, lung cancer and prostate cancer.

The numbers of registered clinical trials show an upward trend. Age disparities between trial participants and diagnosed disease population are present in BPCRL cancer trials and appear to be increasing over time. Equitable participation in clinical trials on the basis of age is crucial for advancing medical knowledge and evaluating the safety and efficacy of new treatments that are generalizable to aging populations.

Peer Review reports

Introduction

Population aging has substantially contributed to the increasing number of new cancer cases worldwide. In 2018, assessment of global cancer burden showed that 2.3 million new cases occurred in adults aged 80 or older worldwide (13% of all cancer cases). Projections suggest that by 2050, an estimated 6.9 million new cancers will be diagnosed in this age group (20.5% of all cancer cases) [ 1 ]. The elderly are the fastest-growing segments of the world's population. Despite shouldering a disproportionate burden of disease and consumption of prescription drugs, the elderly are vastly underrepresented in clinical trials. In particular, older adults over the age of 75 are chronically underrepresented in cancer clinical trials [ 2 ]. Ensuring adequate population representation in clinical trials is critical to generate sufficient data on the safety and efficacy of interventions in all age groups. Unfortunately, many drug trials do not include older adults because of concerns about the safety and efficacy of drugs in the older population [ 3 , 4 , 5 ]. Randomised controlled trials (RCTs) often establish standard clinical practices. The applicability of the trial results could be compromised by the under-representation of elderly patients [ 6 , 7 , 8 ].

The lack of diverse participants in trials is an ethical and scientific issue, because it could limit the application of future therapies. Increasing representation of diverse participants into clinical trials is essential for assessing drug effectiveness and safety. Clinical trials that do not adequately represent the diversity of the population, particularly those most affected by certain diseases, may lead to the results not being generalizable.

Accordingly, it is necessary to analyse the current state of cancer clinical trials and explore the gap between the age of enrollment in clinical trials and the true median age of cancer patients at diagnosis. A study examined age disparities among modern oncologic clinical trials for breast, prostate, colorectal, and lung cancer (the 4 most common disease sites), characterizing the differences between trial participants and the population by disease site. In this analysis, 302 randomised clinical trials before 2017 were included. And this study found trial participants were significantly younger than the population by disease site [ 9 ]. Further research is needed to determine whether the age gap improves over time. Therefore, in this study, we first illustrated the status of all clinical trials on cancer and then characterized the clinical trial enrollment disparities in the most common cancer, focusing on improving enrollment to be more representative of the trial population.

Materials and methods

Data acquisition and processing.

In our study, we used the ClinicalTrials.gov dataset, which is one of the most comprehensive clinical research databases globally. The ClinicalTrials.gov database was frequently selected by other studies to characterize study populations and trends in clinical care and research [ 10 , 11 ].

The trial status in ClinicalTrials.gov registry included active, not recruiting, by invitation, recruiting, suspended, terminated, withdrawn, completed, and unknown. We included completed clinical trials in our analysis. Oncology clinical trials up to September 13, 2022 were searched on the ClinicalTrials.gov website. During the search process, the following advanced search parameters were utilized: other terms: “cancer”; study type: “all studies”; status: “completed”; study phase: “early phase 1, phase 1, phase 2, phase 3, phase 4” and study results: “with results”. A total of 7747 clinical trials were yielded. All 7747 clinical trials were used to analyse the current status of cancer clinical trials. Among all the clinical trials, the phase 3 trials targeting therapeutic intervention were screened to analyse age disparities among cancer trial participants (Fig.  1 ). Due to all trial-level data were publicly available, informed consent was not obtained.

figure 1

Flowchart of clinical trial screening, eligibility, and inclusion

Data evaluation

To provide information on the development and status quo of cancer treatment in the clinical setting, study entries were sorted in ascending order according to the date on which the study record first posted on ClinicalTrials.gov. Furthermore, common standardized study parameters were evaluated, such as study type, study phases, ages eligible for study or molecular profile restriction [ 12 ]. To provide a more in-depth description for the dataset, we also evaluated the study entries and categorized them according to additional parameters such as recruiting country, sponsoring country, or industry sponsor.

Trials targeting a single disease site of breast, prostate, colorectal or lung cancer were eligible for the analysis of age disparities among participants in the BPCRL cancer trials. Clinical trials that did not provide the median age of participants were not included in the study analysis. To avoid information bias, the two individuals performed clinical trial screening and parameter identification independently. Finally, the two individuals compared decisions and resolved disagreements through discussion.

Statistical analyses

Statistical analyses were performed at the trial level (each trial is an observation). Trial factors were summarized by frequency and percentage. To analyse the trend of the number of trial registrations over time, we calculated the annual percentage of change (APC) and average annual percent change (AAPC) using the method of joinpoint regression analysis (Joinpoint version 4.9.0.1, February, 2022). Joinpoint regression fits a piecewise linear regression model, which is a special case of linear spline [ 13 ]. Early phase 1, phase 1, and phase 2 were combined as early phase, and phases 3 and 4 were combined as advanced phase [ 14 ]. The median age of each trial was compared with the median age of the relevant disease site according to the NCI Surveillance, Epidemiology, and End Results (SEER) database [ 9 , 15 ]. The median age of SEER by disease site was also matched to the trial enrollment time [ 9 ]. For each trial, the difference in median age (DMA) was calculated as the trial median age minus the population median age. Independent-samples Mann–Whitney U and Kruskal–Wallis tests were used to compare the DMA of different groups. P  < 0.05 was set as significant and all P values were 2-sided. Analyses were performed using R 3.6.1.

The current status analysis of clinical trials on cancer

From 2008 to September 2022, a total of 7 747 clinical trials were registered on ClinicalTrials.gov. 1 551 146 participants were enrolled in the 7 747 clinical trials. Of these, only 17 185 participants were 60 years of age or older, and 1.50% (116) of the studies were clinical trials for the elderly aged 60 years or older. Of the 7747 trials designated with a phase, 79.02% were early phase 1, phase 1, and phase 2. The advanced phase included 1625 clinical trials, accounting for 20.98% (Fig.  2 ).

figure 2

Detailed trial phases of the 7747 clinical trials on cancer

For the trend analysis of the number of trial registrations over time, the APC of the number of trial registrations showed two periods, both of which showed continuous upward trends (2008–2010: APC = 761.02, P  < 0.001; 2010–2021: APC = 9.70, P  = 0.001). The number of registered trials had been increasing from 2008 (3 clinical trials) to 2021 (760 clinical trials) (AAPC = 50.60, 95% CI 36.60, 66.00, P  < 0.05). (Fig.  3 ).

figure 3

The annual percent change (APC) and average annual percent change (AAPC) of the number of clinical trials during 2008–2021. The solid lines represent the fitted values of the joinpoint regression. The annual percentage change (APC) P value corresponds to testing whether the APC is different from zero. Average annual percent change (AAPC) P value corresponds to testing whether the AAPC is different from zero

Age disparities analysis among BPCRL cancer trial participants

Three hundred twenty-two trials were included in the age disparities analysis (Fig.  1 ); these trials collectively enrolled a total of 293 267 patients. For all trials, the median DMA was − 8.15 years ( P 25 , P 75 , − 10.83 to − 2.98 years, P  < 0.001; Table 1 ). The median DMA were − 9.55 years ( P 25 , P 75 , − 11.63 to − 7.11 years), − 7.10 years ( P 25 , P 75 , − 9.80 to − 5.70 years), − 9.75 years ( P 25 , P 75 , − 11.93 to − 7.35 years), 3.50 years ( P 25 , P 75 , 0.60 to 4.55 years), respectively, for breast cancer, colorectal cancer, lung cancer and prostate cancer.

There was no significant age differences between industry-funded trials, with a median DMA of − 8.32 years for industry-sponsored trials compared with − 7.00 years for non-industry-sponsored trials ( P  = 0.169; Table 1 ). In addition, there was no significant difference for age disparity between international multicenter trials and non-international multicenter trials ( P  = 0.113). Trials with age restriction enrollment criterion (42 of 322 trials; 13.04%) or restricting molecular profile criterion (171 of 322 trials; 53.11%) were associated with larger DMA (Table 1 ). Among therapy trials, those that conducted with targeted therapy were associated with a larger DMA, followed by chemotherapy and surgery.

Similarly, sensitivity analyses of US-only trials showed a median DMA of -6.35 years ( P 25 , P 75 , − 10.00 to − 0.33 years, P  = 0.010). The median DMA were − 10.30 years ( P 25 , P 75 , − 12.00 to − 1.50 years), − 6.60 years ( P 25 , P 75 , − 10.10 to − 5.90 years), − 6.70 years ( P 25 , P 75 , − 7.00 to − 5.00 years), 2.00 years ( P 25 , P 75 , -1.65 to 4.60 years), respectively, for breast cancer, colorectal cancer, lung cancer and prostate cancer (Table 2 ).

Our research illustrated the status of all cancer clinical trials and analysed the enrollment disparities among the most common cancer trial participants. We found an upward trend in the number of registered clinical trials. And the age gap between trial participants and the diagnosed disease population was present in BPCRL cancer trials.

From 2008 to 2022, there was an upward trend in the number of clinical trial registrations, which could be due to an increase in the number of clinical trials conducted or an increasing number of journals, government funding agencies, universities, and hospitals required trials to be registered. Among all clinical trials, relatively few had been conducted in the elderly population only, which was consistent with other reported data result [ 16 ]. The Annual Report on the Progress of Clinical Trials for New Drug Registration in China showed that the trend in the number and proportion of clinical trials in the elderly population remained consistent when comparing data from the last three years. Clinical trials conducted only in the elderly population accounted for no more than 0.2% of all clinical trials in all years [ 16 ]. This reflected the enrollment disparities in clinical trials.

Enrollment disparities in clinical trials have been recognized for many years. While two-thirds of cancer patients are over 65 years old, only about 25% of cancer trial participants reach that age [ 17 ]. Ethan et al. reported on the factors associated with age disparities among cancer clinical trial participants. They found that trial participants were significantly younger than the population by disease site and the age gap was greater for industry-funded trial participants, which was consistent with our findings [ 9 ]. We also found that age disparities between trial participants and the diagnosed disease population appeared to be widening following the BPCRL cancer trial reported by Ethan et al. in 2017. This is true not only in the field of cancer, but also in other disease areas, such as cardiovascular diseases (CVDs). CVDs are the leading cause of death globally, causing an estimated 17.9 million deaths each year [ 18 ]; and 65% of those diagnosed are over 65 years of age. Despite these statistics, only 42.5% of participants in clinical trials for cardiovascular disease are over the age of 65, and 12.3% are over the age of 75 [ 19 ]. The participation of these older populations in clinical trials is also low in research on Alzheimer’s disease, arthritis, epilepsy and many other diseases [ 20 ].

The key reasons that the age of clinical trial participants is lower than the age of diagnosis in the population are typically due to a combination of challenges and barriers faced by both sponsors and older adults. These barriers include comorbidities and polypharmacy. Both may affect the attainment of trial safety or efficacy endpoints. Operational challenges include difficulties in recruitment or retention patients, obtaining informed consent, financial constraints, communication issues (e.g., hearing difficulties and visual impairment), and physical inflexibility, which may limit transportation options to clinical sites. This barrier has led to limitations in age-based exclusion criteria and a preference for including younger participant with a low risk of adverse outcomes in clinical trials [ 21 ]. In addition, older adults are more likely to experience adverse effects due to changes in pharmacokinetics (PK) and pharmacodynamics (PD), possible comorbidities, and concomitant therapies that may interact with investigational drugs. These adverse effects may be more severe or less tolerate and have more serious consequences compare with younger participants [ 22 ].

The inclusion of elderly patients in clinical trials is undoubtedly important. Decentralized clinical trials (DCT) could reduce barriers and facilitate appropriate participation of older participants. By conducting clinical trials remotely, participants could participate in the research from their own comfortable homes. A recent survey reported that 74% of seniors preferred this option to a clinic visit [ 23 ]. The Food and Drug Administration (FDA) also issues DCT draft guidance and encourages sponsors to broaden cancer clinical trial eligibility criteria to enhance the generalizability of trial results and develop strategies for recruiting patients that reflect the intended population [ 24 , 25 ].

This study had several strengths. Our study described the status of cancer clinical trials up to 2022 and analysed the age disparities among BPCRL cancer trial participants, which provides evidence to support the inclusion of more elderly patients in clinical trials. Further, in the data acquisition and evaluation, two individuals independently performed trial screening and parameter identification to avoid the information bias. Meanwhile, our research had several limitations. First, selection bias could arise from not including clinical trials registered in other registries, such as International Standard Randomised Controlled Trial Number (ISRCTN) registry, European Union Drug Regulating Authorities Clinical Trials (EudraCT) Database. Further validations in different clinical trial registries are necessary to increase the strength of medical evidence. Secondly, we only considered completed clinical trials with results, and thus we were not able to analyse whether the age disparities improved in more recently initiated trials. It is required to conduct further studies from a wider range of data sources. Third, the disease sites included in this study represent the most common cancer, and these sites may not be representative of the entire cancer trial. Additionally, the median age of the population by disease site was based on US SEER data. The majority of included trials (230 of 322; 71.43%) were multinational, and 48 trials (14.91%) were enrolled in a country other than the United States. Therefore, our study was limited by the extrapolation of US demographics to other countries. Nevertheless, we performed sensitivity analyses of US-only trials and obtained the same conclusions. Moreover, the median age, as an indicator, provides limited information on the exact proportion of elderly patients in a certain study. The median was chosen because of the heterogeneity in the age distribution reported by each trial and was compared as a common indicator for each trial, which was also consistent with the previous studies [ 9 ]. Lastly, SEER captures patients with relevant diagnoses, not just those treated; the median age of SEER may also disproportionately exclude older cancer patients due to a number of possible factors. Consequently, this analysis may underestimate the extent of age differences among trial participants.

Conclusions

Our study demonstrated future cancer clinical trials need to include a wider range of patients on the basis of age. Equitable participation in clinical trials contributed to advancing medical knowledge and evaluating the safety and efficacy of new treatments that are generalizable to aging populations.

Availability of data and materials

The data that support the findings of this study are openly available in the ClinicalTrials.gov. Database at https://clinicaltrials.gov/

Abbreviations

Breast, prostate, colorectal, or lung

Difference in median age

Randomised controlled trials

Annual percentage of change

Average annual percent change

Surveillance, Epidemiology, and End Results

Cardiovascular diseases

Pharmacokinetics

Pharmacodynamics

Decentralized clinical trials

Food and Drug Administration

International Standard Randomised Controlled Trial Number

European Union Drug Regulating Authorities Clinical Trials

Pilleron S, Soto-Perez-de-Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601–8.

Article   CAS   PubMed   Google Scholar  

Singh H, Kanapuru B, Smith C, et al. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration. JCO. 2017;35(15):10009–10009.

Article   Google Scholar  

Langford AT, Resnicow K, Dimond EP, et al. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s community cancer centers program. Cancer. 2014;120(6):877–84.

Article   PubMed   Google Scholar  

Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33(32):3826–33.

Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois cancer center study. J Clin Oncol. 1994;12(11):2447–52.

Pang HH, Wang XF, Stinchcombe TE, et al. Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol. 2016;34(33):3992–9.

Article   PubMed   PubMed Central   Google Scholar  

Freedman RA, Foster JC, Seisler DK, et al. Accrual of older patients with breast cancer to alliance systemic therapy trials over time: protocol A151527. J Clin Oncol. 2017;35(4):421–31.

Stinchcombe TE, Zhang Y, Vokes EE, et al. Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute cooperative group studies. J Clin Oncol. 2017;35(25):2885–92.

Article   CAS   PubMed   PubMed Central   Google Scholar  

Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–73.

Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health Funding for clinical trials registered in ClinicalTrials.gov. JAMA. 2015;314(23):2566–7.

Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 2009;6(9):e1000144.

Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012;307(17):1838–47.

Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.

Zhang ZJ, Schon L. The current status of clinical trials on biologics for cartilage repair and osteoarthritis treatment: an analysis of ClinicalTrials.gov data. Cartilage. 2022;13(2):19476035221093064.

National Institutes of Health, National Cancer Institute, Surveillance Epidemiology, and End Results Cancer Statistics. SEER Cancer Statistics Review 1975–2018: Table 1.11, Median age of cancer patients at diagnosis, 2014–2018 by primary cancer site, race and sex. https://seer.cancer.gov/archive/csr/1975_2018/browse_csr.php?sectionSEL=1&pageSEL=sect_01_table.11 . Accessed: 11 June 2023.

Center for Drug Evaluation. Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2021). 2022; Available at: https://www.cde.org.cn/main/news/viewInfoCommon/1839a2c931e1ed43eb4cc7049e189cb0 . Accessed 28 June 2023.

Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383–9.

World Health Organization. Cardiovascular Diseases. Available at: https://www.who.int/health-topics/cardiovascular-diseases . Accessed 28 June 2023.

Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA. Exclusion of elderly people from randomized clinical trials of drugs for ischemic heart disease. J Am Geriatr Soc. 2017;65(11):2354–61.

Herrera AP, Snipes SA, King DW, Vigil IT, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100 Suppl 1(1):S105-12.

Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6(4):184–9.

Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.

Earl JK, Gerrans P, Hunter M. Better ways of assessing cognitive health. Brisbane: National Seniors; 2017.

Google Scholar  

US. Food & Drug Administration. Decentralized clinical trials (DCT) draft guidance. Available at: https://cacmap.fda.gov/drugs/news-events-human-drugs/decentralized-clinical-trials-dct-draft-guidance-06202023 . Accessed 28 June 2023.

U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence. Center for Biologics Evaluation and Research (CBER). Inclusion of older adults in cancer clinical trials guidance for industry. 2022.

Download references

Acknowledgements

Not applicable.

This study was supported by grants from National High Level Hospital Clinical Research Funding (BJ-2023–208) and the capital health research and development of special project (2022-2Z-4055).

Author information

Authors and affiliations.

Clinical Trial Research Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China

Shuang Zhao, Miao Miao, Qingqing Wang, Haijuan Zhao, Han Yang & Xin Wang

You can also search for this author in PubMed   Google Scholar

Contributions

Z.S. and M.M. conceived the idea for the study Z.S. and Y.H. performed trial screening and parameter identification. Z.S. performed the data analyses. Z.S., M.M., W.Q.Q., Z.H.J. and Y.H. interpreted the results of the data analyses. Z.S. wrote the manuscript. Z.S., M.M., W.Q.Q., Z.H.J., Y.H. and W.X. made critical revision of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xin Wang .

Ethics declarations

Ethics approval and consent to participate, consent for publication, competing interests.

The authors declare no competing interests.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Zhao, S., Miao, M., Wang, Q. et al. The current status of clinical trials on cancer and age disparities among the most common cancer trial participants. BMC Cancer 24 , 30 (2024). https://doi.org/10.1186/s12885-023-11690-9

Download citation

Received : 30 June 2023

Accepted : 28 November 2023

Published : 02 January 2024

DOI : https://doi.org/10.1186/s12885-023-11690-9

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

  • Current status
  • Clinical trial
  • Age disparities

ISSN: 1471-2407

cancer and its types research paper

  • Share full article

Advertisement

Supported by

What to Know About the Science of Reading

An effort to overhaul how children learn to read, known as the science of reading movement, is sweeping the country. Here’s where it stands.

A third-grader sits on a bean bag chair with a book at Good Springs Elementary School in Nevada.

By Dana Goldstein

During an era of intense politicization of education, there has been rare bipartisan consensus on one issue: the need to overhaul how children learn to read.

Over the past five years, more than 40 states have passed laws that aim to revamp literacy instruction. And on Wednesday, Gov. Kathy Hochul of New York announced a proposal to require schools to use “scientifically proven” reading curriculums by 2025, and to invest $10 million in retraining teachers.

The effort sweeping the country is known as the science of reading movement. Here’s what to know about it, and where it stands.

What is the science of reading?

There is no single definition of the science of reading. But the key idea is that teaching strategies should align with a wide body of cognitive research on how young children learn to read. That research , amassed over decades, shows that in addition to a broad vocabulary, children need to understand phonics, or the relationship between letters and the sounds of spoken language.

While some children seem to pick up reading naturally, research shows that many need explicit, carefully sequenced instruction in the letter combinations and spelling patterns that form the English language. Without explicit teaching, some students — including children who are read to every day in homes filled with books — will not become proficient and confident readers.

Proponents of the science of reading, including leading brain researchers and parents of children with dyslexia, have pushed hard to change instruction over the past decade.

How does it differ from other teaching strategies?

The science of reading represents a significant shift for the nation’s school system. For the past two decades, a school of thought known as balanced literacy dominated how colleges prepared future teachers for the classroom and how those teachers taught.

The scholarly roots of balanced literacy are in the education and English departments of universities. Brain researchers, examining reading with M.R.I. machines, worked in other departments. As is common in academia, the two groups rarely shared ideas or collaborated.

Balanced literacy emphasizes the importance of surrounding children with books and allowing them to spend quiet time reading literature that interests them. It includes some phonics, but the instruction is less structured. Letter-sound relationships may be introduced as they come up in stories or through classroom games, instead of in a sequence designed to build foundational skills.

Balanced literacy curriculums have often relied on teaching strategies that have been discredited , such as coaching children to guess difficult words by using pictures and the first letter, instead of sounding out the entire word from beginning to end. Educators and researchers have said that technique leaves children ill-prepared to tackle more difficult texts, without illustrations, as they get older.

Critics have also argued that balanced literacy shortchanges vocabulary and knowledge building, by allowing teachers and students too much freedom to select reading material, instead of guiding them to challenging texts that build knowledge in various subjects such as social studies, science and the arts.

Three major American leaders of the balanced literacy movement — Lucy Calkins, Irene Fountas and Gay Su Pinnell — have rolled out changes to their reading curriculums under political and financial pressure from the science of reading movement.

But they have also warned about what they see as risks of too much phonics instruction and have pointed out that past phonics-centric reform efforts, such as the Reading First program under President George W. Bush, yielded limited results.

Is the science of reading movement working?

In some big ways, yes. States are passing laws requiring instructional change, and curriculums are being revised to include more foundational phonics and richer reading material. Many schools are also retraining teachers.

Universities are shifting, too, by distancing themselves from balanced literacy theorists and promising to change the way they prepare future educators.

New York has been a focal point. Under Mayor Eric Adams of New York City, who is dyslexic, the nation’s largest school district has required schools to abandon balanced literacy and select from one of several reading curriculums better aligned to cognitive research.

But there are many challenges to the overhaul, some of which could affect whether the efforts achieve a key goal: raising students’ reading test scores.

Teachers need to not only be retrained — an investment of time and money — but also be brought along with the efforts so they feel invested in the work. Another big cost is that classroom libraries need to be replaced in many elementary schools, as there are few books within them designed to build children’s phonics skills. Outdated curriculums need to replaced.

Across the country, initial research on these efforts has been hopeful, but limited in scope.

Dana Goldstein covers education and families for The Times.  More about Dana Goldstein

IMAGES

  1. How To Write A Clinical

    cancer and its types research paper

  2. Research

    cancer and its types research paper

  3. 7 Different Types Of Research Papers

    cancer and its types research paper

  4. Cancer Research Template

    cancer and its types research paper

  5. Massive Genetic Map of Cancer Mutations Cataloged

    cancer and its types research paper

  6. Cancer research paper

    cancer and its types research paper

VIDEO

  1. ❤️ CANCER ITS ALL ABOUT THE PERSON ❤️

  2. Final Call For Cancer Biology National Workshop

  3. Master of Cancer Sciences

  4. The science behind cancer

  5. CANCER ITS A HARD NO FOR YOU 🤣🙌🏾😌

  6. PROPERTIES OF CANCER CELLS

COMMENTS

  1. Download .nbib

    Cancer is a disease that begins with genetic and epigenetic alterations occurring in specific cells, some of which can spread and migrate to other tissues. 4 Although the biological processes affected in carcinogenesis and the evolution of neoplasms are many and widely different, we will focus on 4 aspects that are particularly relevant in tumor...

  2. (PDF) CANCER CAUSES AND TREATMENTS

    A: Cancer treatments. Int Pharm Sci Res 2020; 11 (7): doi: Citations (37) References (46) ... It affects approximately 4,00,000 children annually 3 . by 2025, 420 million new cases of cancer...

  3. Classifying Ten Types of Major Cancers Based on Reverse Phase Protein

    By using the 23 proteins, we successfully classified the ten cancer types with an MCC (Matthews Correlation Coefficient) of 0.904 on the training set, evaluated by 10-fold cross-validation, and an MCC of 0.936 on an independent test set. Further analysis of these 23 proteins was performed.

  4. Cancer

    PMID: 29952494 Abstract Cancer is characterized by proliferation of cells that have managed to evade central endogenous control mechanisms. Cancers are grouped according to their organ or tissue of origin, but increasingly also based on molecular characteristics of the respective cancer cells.

  5. New approaches and procedures for cancer treatment: Current

    Cancer is a very complicated sequence of disease conditions progressing gradually with a generalized loss of growth control. 1 - 3 There were only a few options of cancer treatment for patients for many decades which include surgery, radiation therapy, and chemotherapy as single treatments or in combination. 4, 5 But recently, many pathways invo...

  6. Advancing Cancer Therapy

    Metrics Cancer therapies have evolved considerably in recent decades, substantially improving the quality of life and survival of patients with cancer. In this issue, we launch our Series on...

  7. Introduction to cancer and treatment approaches

    Introduction Cancer is the uninhibited growth and development of abnormal cells in the body, and is one of the foremost reasons of deaths throughout the world ( Paul and Jindal, 2017 ). These abnormal cells are commonly designated as cancerous cells, tumorous cells, or malignant cells. In 2018, cancer accounted for an estimated 9.6 million deaths.

  8. Top 100 in Cancer

    Top 100 in Cancer. This collection highlights our most downloaded* cancer papers published in 2021. Featuring authors from aroud the world, these papers showcase valuable research from an ...

  9. Cancer articles: The New England Journal of Medicine

    N Engl J Med 2023; 389:1851-1861. Selpercatinib, an oral, selective, brain-penetrant RET kinase inhibitor, was compared with multikinase inhibitors in advanced medullary thyroid cancer. At 12 ...

  10. Genomic analysis of 33 cancer types completed

    Using molecular and clinical information from more than 10,000 tumors, researchers finished a detailed genomic analysis of 33 types of cancer. This better understanding of how, where, and why cancer develops will inform the development of novel and more personalized treatment approaches. This image shows the uncontrolled growth of cells in ...

  11. Innovative approaches for cancer treatment: current perspectives and

    Introduction Cancer is one of the main causes of death worldwide, and in the past decade, many research studies have focused on finding new therapies to reduce the side effects caused by conventional therapies.

  12. Understanding Cancer

    Type of blood cancer that originates in lymphatic cells of the bone marrow. Cancer that begins in cells that line certain internal organs. Bethesda, MD 20894 HHS Vulnerability Disclosure In simple terms, cancer is a group of more than 100 diseases that develop across time and involve the uncontrolled division of the body's cells.

  13. Review of cancer from perspective of molecular

    Cancer in the broader sense refers to more than 277 different types of cancer disease. Scientists have identified different stage of cancers, indicating that several gene mutations are involved in cancer pathogenesis. ... Initially, we searched research papers using keywords such as cancer and molecular process, cancer and treatment and ...

  14. Research articles

    nature cancer research articles Research articles Article Type Year LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells Kumar et al. show that the...

  15. The history and advances in cancer immunotherapy ...

    Multiple cancer types have shown sustained clinical responses to ... , 177 is on the leading edge of tumor immunology research due to its high response rate to ICI therapies. 178 Tirosh et ...

  16. Cancers

    1. Introduction. The global incidence of cancer has increased to an estimated 18.1 million new cancer cases in 2018 [ 1] and is expected to reach 25 million by 2040 [ 2] with the largest impact in low- and middle-income countries [ 2 ]. Cancer care is distributed unevenly among countries [ 3 ], and, due to its complexity, only specialized ...

  17. Inflammation and Cancer

    Abstract. Inflammation is often associated with the development and progression of cancer. The cells responsible for cancer-associated inflammation are genetically stable and thus are not subjected to rapid emergence of drug resistance; therefore, the targeting of inflammation represents an attractive strategy both for cancer prevention and for ...

  18. Cancer Treatment Research

    Research to improve CAR T-cell therapy is progressing rapidly. Researchers are working to expand its use to treat more types of cancer and better understand and manage its side effects. Learn how CAR T-cell therapy works, which cancers it's used to treat, and current research efforts.

  19. New approaches and procedures for cancer treatment: Current perspectives

    Among the obstacles of cancer, drug resistance and its deliv-ery systems are the most problem in cancer cure and decreas-ing signs and symptoms; but currently, there are many approved treatment approaches and drugs. The efficiency of conventional cancer is reduced due to tumor pathology and architectural abnormality of tumor tissue blood vessels.15

  20. Types of Cancer

    In the United States, cancer has a major impact on the society as it occurs in large groups of people (Fig. 2.2).In 2018, 1,735,350 new cases of cancer (Fig. 2.3) are estimated to be diagnosed, and 609,640 people may die from cancer (National Cancer Society, USA 2018).India ranks third in cancer cases after China and the United States, and more than one million new cases are reported each year.

  21. Focusing on the cell biology of cancer

    Nature Cell Biology aims to be a forum for papers that employ robust models and provide mechanistic insight into fundamental questions in cancer cell biology. Nearly all our cancer biology papers ...

  22. RNA sequencing: new technologies and applications in cancer research

    Over the past few decades, RNA sequencing has significantly progressed, becoming a paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing to single-molecular, single-cell and spatial transcriptome approaches has enabled increasingly accurate, individual cell resolution incorporated with spatial information. Cancer, a major malignant and heterogeneous lethal ...

  23. Stress and cancer: mechanisms, significance and future directions

    J. Neuroimmunol. 346, 577311 (2020). This review describes mechanisms by which stress affects specific hallmarks of cancer, emphasizing how stress is an integral part of cancer biology. Article ...

  24. The current status of clinical trials on cancer and age disparities

    Objective To illustrate the status of all cancer clinical trials and characterize clinical trial enrollment disparities in the most common cancer. Methods Clinical trial data were extracted from ClinicalTrials.gov website. All searched clinical trials were included in the current status analysis of clinical trials on cancer. Among all the clinical trials, only trials addressing single disease ...

  25. What to Know About the Science of Reading

    The science of reading represents a significant shift for the nation's school system. For the past two decades, a school of thought known as balanced literacy dominated how colleges prepared ...